var title_f2_60_3008="Gingival infiltration in KS";
var content_f2_60_3008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gingival infiltration in Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCqr/6PEgJyqKPyAqCUnnjvxUIkwuM5HT8KjlmAHv614yPrFoQy8E9euTWTencpx37VfnkGOSM4xWNfTZHWqSM5vQrWqCW6CdTXZ6dpjFPu9QOawvB1j9quw5Gepr1jTtNAhXcoJHIOO+KmpOzPNqSszjJdKkzlenTpVmKzZY+Rn612U9iAhwMkjqRWTNCB0HB4NQ6lx0pHPyxfN3qtLBjPBrWnRg5BqCVCccZzx0qkd0XYzPJG3HGfelSHK88HvjnFXdhyCo5oVBvzwBn8KTLckVksmPzD6itW0tBszxTBcRxAFmX8asxX8bDANYzZzzm2tBt1aKyMGAx0xXNatZ5GCoz2rrTco6Dknj61kaioZGx6djUQZMJNbnCwf6JcPCx+RuV5/lVoOokG5dynrn1qDxIoQxyLnKnqKoxThsNk5Hau+m7o6qUtbGyrcgKwFTiTggn5gMday4ZMncvzDHc1YAB+ZevT61qkauxt6PqlxDLtiZll6qSeAa6zTtcubdFzK28Hduzjn146VwFvgSAj5Spxz3rTgunCnJA7AeopRWpjVpxn0PQbrxJe6hEkVzeTTRKdwVmyM1TmvQNqPnJ7gjp6Vy0NziDCkgYzimG9ZiNxBB5A71RzqhFbGlqF2okK5JJ44rFuLofdUAnuaju53BYk7mPHSs9ySM5weh+lCR0Rgki4soGwyYApjyqYzk4IyTnv6VXmkKngZx3z0FRTuAgOMknJFX0GtxQ8ZPyLuPo3QGnT3kNqFOMseAiVnXE4VC4B3FuAO5pbKydz5jjMh547VzyqWLnJLQdLNc3mDI3lp2Rf61VNkzE4Hfv1roYLA7Rhe2cVcttM8zsdo9ulZ87ZhddTlI9MO4AgEfyqwNIBGdvHfiu4g0mJfvjrVhtLTnaue2RS50TzxPPH0fdn5ent1qpJoyngxjj2r0p9OCJyufQms+4sd2Sq4P0o5ykoyPMrvw6yyCWBQHQ8YHWtvwvcFGEM2VkU9D2rpTYnzMBPmzz9Kjn8PCY7o18uQdCKmU7qzIlRSd0btsQ8Q6dOaq3UZJIHWqNo9/p67bqJnjH8S81q297az4ywBOOGGKx5gg3BlHy2wOB+PehYiGPpya2mihdcoUJ7Amq8qoGJXGKHI6VWTK0S8+/Q0sgxHgYUfyoeZU6EVUnvkxgMBnrmnclzuMcl2ORn2orMuNRjQ4z7cUV1UKEqibUb/OxlKrYuSSY798VCZeOo6dDWcbnPPc0x7g4IHb060kinOxPcy4U8/nWRKJLmUJGCSxxxV6K0ubxgkakAn0rtvCvhLyyslwvzdgRSlNRMalSy1LngbRja2qs6nLLx2Nd5EAi7eBiks7RY4lVQOg6Cnuvy7hyMdu9ckpNu558pczuR3B4B5Hpmse8RNmc8VbvJjGDyeelc/fX+0EE4Pbmqjc2pxfQgvpAJCM8CqjSjjuOpJNUby+DMST055rB1DWCD5cXLE4610RT2OvZG5c6lHFkBs8/jVH7ZPOxKfKuetY0Eik75DvY1dS6UAAjr1961dHT3g5kaMcasAZHJ+lbFtb27x8tk+9cwb4AEcYp0eqhCNpIGMcVzzpLoOWqOmaSO3GOnpk8Vn3l0pVsHn3Pesm41bzFIO0nHWsO5vzCzYJ55PNRGD2MUuUPEs4eErkelZce7Z8vQcVXuroXt2kcZ+VTubnpVuBzkDnpkiu2lGy1NqbuyzbyNHEFZAB27ZqzE7M+5GwqioZPLZCBzzxUcEyRsOeCcHtVyOmJsCQDG08njHqKuAl0zkAcZ4rJhm2EDCgnBGf5VrWsoOVZeP8aUdwloWFHTJAIP55p4QFmYgkL0I7VHtCPvJyrEAEdabJONhjjJHqOhNaWsZ3ZHPMkY7E/7XU1S+0+YxU53EdT3qO8cPtkV8AsFweaTyzlXUoMEZ56ClZmuiQ24lKDL5LEY/Gq0kwOHcncOqjpipGhMrt5jYIOUz/OovLdMmTBwf19aUk7GfMrjbZTc3hLY2px+NdPYxLgDrjjtXL6O4DS7jxvOTXS2zlgCOARnHrXFPc5pTvubUflrgHvWtp4UMuAFU5yaxbQAsGl+g+lasUywnK9PasZSfQybb0NAWXmMSu5+eCx6VZjt1gIMgO3oy9QaowaljJx81X7fU45XCy4weM0KDkRaSKjSJJkKpwOgb0qNYUYjdz24HWrl9aq372FqoJP5cm2ZQp6bh3qrSjujSMtNCU2CHkKfY9qkW22ZJjHHNW45FKZByuOmakjZf4h8uKlle0bIYbWOQBWUdPrUF94ctpgSYxn/AGeK1FlVVUBAB0z6US3eEyFx25NQ0ReV9Dk5/DSxE+VLIhHv1rLuNHuE/wCXlziuqnvnkyEXBHXPYetZ8vmPliuTRY6YKXU5C5067wf9Jcj1IrEvtPvlUlJw3HGRXeyxFzhh830qjdW5yTj86uLsbcqZ5XfjUIJN0gyoPJXtRXc39jvU/L7Z9aK9jA4xUYtOVvnJfkmclTD3ejLtv4ZfzBuxj6101l4RgMasQCR2xW7HAGBwOh+ua1LdRGgx6V5bqE1JN7GVpuiRW4wqKOT1FbsKInA4AFR78DqAMYwKRpxxg4Fc8p3ZzyTe5fh688jPTNQ3twiRHJzgZ/8A1VRa9C5G78c1j6pqACNzgYpwIVNtlXWtSAZtpI+tcfe3nBLN9M0usX2STu/Dua5e7vS2TuworphA7UlFE+p6gFU8klulULdtyEv1Pesi7uPMnLFshecdqiW/wMBhmu6nFLUwnNt6G3JP5fyh+PrURvQB94/nmsOa8LnhiaYvnynCowz68UpajUmbT3yjJ3E1G98T369Kow2dw/BHIOK2LTRlZ0WSQ5PJx3qOS7G5tGbPqQjwHb5+gUdT+FMWC71BQfmhhHJz99v8BWtf2dvbXGy2ReOvqT9e9W7OMhMKD+VWoJMVnJXZj2toltMqbSBn8T71oEKgkTHCtyaluowlypBPpjpioblcOXdhtbqfpQddJKyGk+X823KHr7URhZdg4znP0+tPU/unL/ODwKISLcsq5MZHp+lLc6Ey3D93HAK5OfWrunT7hkAlhxkGqiSI8O8t24WpdPKxRiUYIzjpSS1BvQuSysZBnIye3Sq0pcTuoO7cOnpVmZ/MDsDtyf8AOKgt8tLgtls9fWtV2IW1yAKA2JByeQOtSSsqfKi8P1HoallIWaFWwSpyVHXHrVefAlJU4xzz6VV0GrFR+WMuS4xwB0AqvM5kKhfXJPqKekpYmNB8zjDU+VSCCoBGcH0qJMixh28jQ6msTcA5fB711djcjYGzz/Kub1K1d2R4eJkGY27H1B+tLp9/ldrAqw6qeorlqQuccvdZ2KXPRhnHpViO94wSPxrmheYAyasQ3e9evP1rP2YJnUR3AYcnkHFKZymDk/hXPx3ZUj5qnW++Xls1SiWjqLPU3jwGJZe4NaSz290Mptz6MK4b7YARgkVLFqBVs5J9q6IxvuS49TpzcS2cuJARATwc9K0Y7pJEDA4FcxFq3mKyTAMh/P8ACoxePBNsU7lPI+lYVqHLqtgj7z8zsvtC+XjoSPxpYWEmAScelYEF6WQZPIrTtbgHnca5zS1kahtVZSRzjmq09ttUAAAehq1bzB2wRke1Wntt64TOPepaJU2nqc3LbnaxjTc3YE4BqtPajBXOfrXSSWjIuVwc9xVGWA4BI5HpU3NlUuc1NZ7segH+c0VuvADzziiuuhKyev8AX3obmdDFBtPynNOlKomBzSM5CjZj6E9qpSnOSSM1y2OZ6kkkwAPPX0qnNc5Y8/nVe6uFDHt2PtWVdXoyc5yPwo5QUSxeXm3v0/Wufvr4ktk9KbeXfmFsnGKwb+4O5mLHFawgXsUtXuvnPPHWubv7tipWMZc07VLwtIWwQPSo9LPlzPNJGsnmxtHtcZC5HB+oODXXCJlKTeiLOj+F9R1MRuscsVvMy/6VLEwhAaQRhiwB+XedpIzg+9dDrXwzuNCtbaTWNUsLKe4ErrBcMUJRAxDDGThiu0ZAOWX1q5o/jDXdK0OfTNMvpraxlOXRDkjIO4KT9wNnJCgdAc55rMuLiS9n86eR5GY75HdyxLepJ710vlS0CnSm3d7HW+Hfhxoomvk8TeJbOws7IRjzrR1Zp3kRWUrkZKqWUNgeoyMEjH1e20Sw1y/XQvMvdJ2+TbS3gG9sqMycAYO7cRwOMZHWstpx5x3AEgcAdKpXl0Wba3AB45yKjmsjaNF812yeMAyAYUKpPfrRDcCOQ8Hjg+v0rOaYLFlz7DNRC4KFckhQc5qLmrgjRuJCZnLqRlu/HHpU1tIY+M49j6Vjm8CyFmbI7Z6mnC8IZdpJUAZJ60JkuJp3DbxvwSw496V1Z4yjEY+8MisZ7wklRjn5h6U9dQYMoJyPY5qhrQv5aJMNtz/TNCuJDtbgE5FVmuUYAsOeopglDKXGQQODnvSZomXldljfPTd3HWrUVyVgUhApz096q2ziVEYNwOtK4Em1gCVBySw4NQr3uXzLqa7NvHzAEY/OmWxH2hXxtAU445b61SEzDaBjA/WpFnC4y+NvGPTNakX0LsxUqhAwRmqF2DM6EkgpUxuCzKzKoBGB/Wqks+yQhQeneqeouayHQs0YI+8pHf1HpVuFmK4kUK2Cw+tZ6vtUHdgqcjNXwN0asTtO4kD/AD1rOSGnoTGMBly2G2gnHasu+sFkIZSUPVXFWJJ23EAEyE8kemOgoluswgEfdPHbrQjmqwuYTXMsMhiuBsOcb1HDf4VLDelG68GtCaBZICHClsZPvWVLp74EkByh/Sh0+qOVSadmakV7nHNStdEqcGuXM7wthg30xU0N6WIweaUUXzWN/wC0vuwT1/Wr1qSTmVsDpisOG5CDGPmPOasRXOTx1z0raMQc7nWw3EcZzwO9U728JuFaNuh61iyXpS3PPDcU2wlMk2CeKiu09Ap73OrtLhty+nvWtaXJ3DDCudTco2gAGr1k7bhn+dcMkdidzsrG4YFec89BXQ2l2HBDYI9a4m1nPBNblrNkD0zzzWLRlUjc6Btjrw2cccVUlhJJ9PpS20u4ZGAalQtIFORkHuKOUyTaKEkaq3AyQfyoq88auSrDBHf+tFdOGqVYJqmkx8ye5DJMQuOPTjvWZPNmQ4JPvmn3c55UEEjr9azZ5cMx4+pNc6Gu5W1CbbnBbJrAv5wOAfripdVvNpbOCexzWDJM7ckVoolXsSM5Me49KwNXviEfH41oX10I0289ORXNy5vLnA/1eefetoxIbuzNi3XUu9x+7HT3rZSMZRQM0C3wvCgegFWol2hGPqa1TsawpkgXbCRkkdzVaSQxgqpJDDFXECvHkrkZxzVCZgjEAcjgUXuzq5LIjM+wKGbnpk/yqpNcZ65AB4Peo5juky2R6ZqncHLjrj60xXJZLwnAxnB+tQ/aHcsTk5HFQMcAjjJPWoWcn3NFiWy00zOwJOPY96lSYkgM3I6cfpWZvOeuKDLg9cfWmkZtmrJJlux7cnpUZfByWO4c5qkk53dc56809iSnPB9qqxNy9HOTkZYseTVr7SVixn8awjIQQRxVqK74BPOB+tJlJnRWsv7gAHOOAavfaYwq5Ycetc5a3RVCeh9Ke92WXBIxjOSKlDbN03Mb5CnGPSmuvm5bqRwDWRHcIExvPToTzVqC7O1iuCFGapML22LMspjgVXZhIT8oHaq8jSCRgWywOQT3qG5un2iQYyOcY6VFFcKOZTkjjOe9UhNmmmHCeZgY6885qy06pJGihiuATk8596yYZwAzDhccZHb0qRJ2aTeMFx1A9KUrBFsvSsXIkG7cvUHuKjE3H7wkBv79QJdAKA4xk9T2qCS4IUAMSB3I7VIpO5oec20fPlTnjPTNWIJQbZ9gxj06CsF7nKDgE9Pwq3aSblAZhmrTMJRvuWJrNZmAKjcefrWZfaYY/mjyjgZ+tbfmt8mOV7jpTJ2WSNBwSOCarQzcX0OW8+dCQwYkHmrdrebldt+CvOO9WL23V5CYwVOeG/8Ar1UvLYO0u1CqjkPgEhffH86V7ENEn21psAk4zwK2NMkIQMPyrkraRo5yjn5lPrXR2MxUr0ORisZavUuOmh1Ec5YL1xjrV+GYYGCd1c7bShcqWOKv2k24DBNYyR0QZ1FpMxAySB1rfsZSFzkdO9cfaSlWBBNbVrOwxnpWLRo9TqYboxtgH71Wo7mRTg8GuZ885GclfWtO3vJCVAIx34qTNwOjbLqCDjuc96Kg064+Tawy3Y0VrThKS905nLldjmLu4KtyeP1rHur3bkdVGadqU+DnNc9e3QVHYnGOBzUxib9CtqN5mYCqk9179KzL+ckmQngVWJuby2nnt0JhhC+Y/puOB+tdEYmblqOurlrpykf3c8mrVrAFAA4x1PrUFhb4Azknv61r20PzDIrRRsjWEOpWkiCruHA68U2SQJGoHGD1q1qBCxcA9e4rKd/m6j2qTptYuzpthLKQPY1i3EpTtyea0ZJk8gB2YnrgVjXMnmSbVHB4HPShI0crogmmyScCqjuF7UshI5xgetV5CS3AqzFsG+Ynkgn0prDj/wCvSAY5AyanSIn72BTsJlRgcHpmo278VdMYB4wGJwM9KqzAfeU8VSM2MGcDr61Ksp27WyAaiiOTxUkny44AzTJHEjPt71GGwcHr7UwH0z0pQN7ADj1p2BM0oCGXOeTxTJX2s67txzjAzTbRSjOjDqMj0NMuJcscccY49KlIpyJGY7c7DjrnoaljuNiKFxg9vWs95QUClTuzndnt9KYsnZuh9arlJ5jSkudzfeIX1z0pybQPlx7ZPSqCSYQ56+vXNJ52TzS5Q5zQMzKo3Md3p6e9Pa8+UBQxz1PasszH1IHtTfOYt1J/HrRyhzGp9pLAjJx3ApEumQHkNngj0rNV8vkDFOQ88fy6UmrBc1fPI4CjHQ89auW7AAbsYyMVgiQggZPpWnaSb4wCM4PryKS0Bm0bk44xzTkky2Oh65NZ4IHU4z0p6SZPqBxRcXKWblgxG3ntVqxeS1uormAgSxgkEjPVSOh69azWffKoHatOIY+Yg/TrS5tQUL3OZu9PeJxJArMR1jAzke1WLO43hGBrsPDttI+vW0kMYdoQZMMeOh/xFcXeQGxv5EwFjZiUC9MZ6CnKPuqRhL4rG3DIu3OeBWnZSANx065rnraQ7FIAwRitC0lIPORzWDLjI6uzcZ65rVEhB5G3iuf0/d26n3rZhcuSh6njJrJo2UjYtZd42vg+ua1YBjhRlB1Nc9GxVVV/vZxxW9asdq4OAw/OsmhSlY1bWR9wKnge/Joplq+wH0ziikYy1ZwOpT8Lk/X2rmdQuBIcA8d6taldnzGAOea5+5nAZmJrpjEcpEWoy7kKLyTxwOldR4fiSTTdVtrOIwB9HLyhmJ82SN0LN/46SB2JNcfERI/mOpOTgDOMZ6fr2r0HwnGZz53lxsjRz22XwFy8LMOT34498V001YSWlznIA8R5J4PpWnCwcE85AzTAqtDkc4A5NQW8hF0QScMtJrQ7YrQbqbZh696wp5djqwGcHoe9a+qnEQAPzZrn71v3ZI7Vn1KZHc3J3f0FQ26iaeNGJCscEjqBVNpdzsSKkikYjYhO5u49KtIjnLNhYXms6mtho9pPeXMhbyoYVLuwUEnAHXgE/hRqWlXek3ctpqdnc2l1Ht8yCeMo6blDDcDyMgg/Q1PDEsEKFP8AXZzuBwVxVadmDvLMS7MSSWJOT6nuTQ7D5Wiq7JGpeQdfujHWq8l0e2M1DcMzyMSf/rVWkOM461pGNzGpU5Sc3DH+IU0sGHJ61TJJJFORmzjNachyLE826L8AAI5xU88lv9m2iLM5k3ebuOQuPu7enXnPWqCsT9alIIQVGx0p3JrQ2qPIb2GeRTG4QRShCH2/IxypyoPJHBI4yOtQ7SvIPI96mtIPPdlknitwI3kDTFgGKqSFGAfmbGB2yRkgc1Xkbc2QAv0pidjZsCMAzDAwfmqCdIIZHLxhwyEKrE/KT0YYPJHXB49aND1CXTtStLyz2LcW0qzReZjZvU7l3A8EZA4NWdG1bTraS7udU0kardufMi+0XLJGHIbO9VHzgllbGVPydeTSjHW5M5tLYx5I+M52g8gE9RUJOOCfat7xFJpFrc20Ph69ur62W3BeW8gWFxKSdwUAnK4CnknByMnGTz7tk+/eq6kKd1ct2ljeXlvd3NraXM9vaIJJ5YoyywqTgFyBhRn1qpuNWbG/ubS1vYLae6iF1H5UghnZFdMglXUcOpwOD6A1TZ2JO4nJ6k96qxHO1uP3etG6mbiRknNMJPJ6UWB1LK5Nu+tSB/eqm4+p4p6uenpScQjWVy2rZ/OtG0fZhs8elZKv71ZhfIxnoaho6E7mw86tt60+Oc46j+tZschPB596f5mOQeBWZexpWbmS6b0Fb9vgsAxORzXP6EnmNk85NdHjy0MhIx0FK2pUXZHQ+DY913O4OJZMRpnIxluTntgA9ax/FGjNd2srwYaSAPMMfXLfnWv4bIjdck5VWY4Ge3A+pPGafr8u2z1C73vu8pYd642uWHIb3wM5GOldUUnGzOOone55jazkAY4wM8VsQPlsk57isOZPs8sZyQZV34I6DJxVuzmwdpPIPFcko2BM6qxnPHJ3CtiG4yAQQCK5e1mA5zjNaEFyS3H481m0aqVzq45Q4jZjyeuOK2reUoFUtgda4+2uckc9D0rat7jzgoU/MPesZIG7nTxzKrgA5DfpxRWfAQwjYSMNvOB0P1HcUVFrbENnkepXgWQ5NZDS5/eOMowwDn2qvNM1zcNtwfmwM9DVlFLui+WjoFzk9uvX34NdsVYzvdmvDZpIo3FioIUkHGSD1J+lemfCcWsWsW9tdoXDXsERAPADb1PH/AhXC6fbs6MqqhAVyCG/u7T+J4PFXNNv5rPV5JowzvuWQIx2qCOhP0649q0g7O51KHNBxJb63exvLu0fb5kEjwnHqrYx+lZbzFZI5CPmB6elbPiq+iu/Ed9dW8jTLPJ5okbAJ3KCxOOBznisG9yAR/wIUpdTpWyDU23xkr2GRXL3s37ts11JIuLTd0G3OTXGakV85kZio3YJxnAz6VPLqZylZXKykscVpabDhixqnZRBuSeB04rds4SYx2FE5dEXQhd3Y9lGABye5qjer2rY8k7VUDOTVC+hwSOuKhO501I6GBMnt1qtIm3g/rWtLEGU5HT1qjcxEMCR161tFnBONygVz2oWMgjIrRitjIVAUKR1Jbg1dt9M3n5+ikfjVudjBUlcoWdm0jDj8BWvHpuFO769K0rW1WFOgz04FOeTHCjk8ZrFts6owUVcymsUZ/mGayr6ARONoroZGKk9gM1i6gfOY7R93OaqCe5nLcpKPkY8Hp9ajYZUgdKmG4/IgznqD35psgxhlIPJHA61omQ0iJIwIy3XB604JlgMDJ4GKkgGTgnBqYRjJ5AYetO4lFIdp5EWRJnGc4FRSWxuZm8pT+ParCBQSFGfwq1E4iVmzj0x/I1km73E4mJNaPH3HvioTGe9at5OZZGJUBiOccZqiFyeRWybJdJFfZgYNJs454qdlBPTFLtGOOeKdzP2SIFY5571OCQOeOPzqOSMo5BB3VLGfkwRkH17UmVTutGTwyc4IzTy2WwO5zzVRX2NntU9v886juWAFQ4mqkdRoilIQ2Oe2K1oz51wsWQqoOSemazrdlt7bd0wOg/lVu2LRxsnAd/mkbPQelSkUnc6LTpkkmbYyojkRrk7eAOWP5VX1u/jm0YJGT5080rSAnIC7gI8DqOh6+tY/wBoKD5DgBSMEcVW1K7BMQOCqKFG0Y4Hr6nOcmrUrIJq5Q1hRJcbOPkVUXBycKAD/WsqKTY2Mcit2KJZixPAI+XoTnoR+WawriOR5SwB2qdoOMAY68fjUySkc+xt2Vwrr2J7g1cMyK4IHHSuViujC3XB71sJcJLFux8wPUVjJNCvZm9FdbMFTk9CDWxpt0VAA4H9K5iF0xkDOf0rQs58YGcZ4qGi1I7S2vCuRnHpRWLBKGUEk8cUVnylXR5tbRB0XHY5+nrWrbwo8y84VeSQCQAOmRVSwiyETrnoScY9K2LEK07dMAgMWz9OcdT7V0mcNy+sJae6kjfy4ogxDjpjOM/Ss2+n3yCQbux+Y88k81auEJidFUvv4APXLAE+3HYe9MIVhveMAqBHnsiDPB9SaTZ3Q0RFFN5cgQdOtS3D+Z8m4YXof6VBJLDKHeKMqd2FZm6jtxUSb2IJBHoPWhSNrXCwufK82GUlSFJGeorA1SMteMQVwAGOTycnHFdDPYvPtcPhh3rntTjliuR5qgHOFbOcgentzVROeomi1p0IO3+tb1vGOAR8orJsHXgnHStq3lB4PAqGrnVRaSJJl2ID0rPueVIxnIrRl5649PpVGQZYADI61K0N5aoom3Xyzx9KqvbbjzyPetvyy6kDFEVnNk7kYgdcDNNOxhKCZV06zhw/nLIMIdmwDlu27PReucc1qWOnTXVzHa2VvNc3En3YoULux9gOTUul2oubuCESxRCR1TzJThEycbmxzgdTjnivRNQ1Hwvo8rWWnT3ut6bKRNc/Z82LSOqFPJ3AAiFiN525JDDqVydFruZSXK9Fc89e1txpCXH2sC8a48o2TQsGEWwMJt/3SCfl29eh6Gsq4jAHA6V3uo3UniS4/tC8S1+2ySDJhRlMcaxqqx8kgouOCcsTkk4wKz7/AEAvAXi64Py1k5JMn2i2Z57MxLYPpUaQvL+7hRpJXIVVRSzMx6AAcn6Vb1q2ktJDvXHrkdK0vhzrVr4f8aaVq2oFhbWkjSEoSCp2MAeASeT0x+QzXTTfNaxhUdk2jlry0ltUH2qKe3kkUSASRlC8ZGVYAgZU+vQ1RHMg46HtXonxg1aLWPEvmyNLNeKkaiQxGBYrcJ8kRhOSHzli27HzDCqK4IRYYhRWjjZ6GUJOSTYQKW+71HJJIAxUkygkdfx6/SpLS3I/eFchfu5OOadesGlZs5Vj1Oc/WoNRIlVtvBOfvDPNPlKhCIic9s+lWfDy2Z1WxXVGkSwMyi4eEZdYyfmKjuwGce9d5ZfD2bxXf3f/AAgrLeW0cxMcF/cRxXgix/rGXOGXoCRzkj5aIxb2JlNRep5hJCxXcFwR1x/Ooih4Iwf0rpfEmlz+HtWu9K1WMpfWcmyRFbcrcZBVu6kEEHuCKxpTH56lRwcZBORn60ddS1qrlI4ztPHGKRUwx68VLMo8zIK/3iB29qQAnjPPSi5LRWfk9fxqSJflI5x61KUypIHJ71MkQWLDDkfpRcnzK0RWKTLvhT8rfKGODwcA8ZpdOK/a48ZCBieeoH+NNuBgdec0mnRO9xhAD/nvT6EPSSt1OogP2i6RIyfLBzn0x3rRd4kysBJyOcnk1l20TQRAZyx657Vat1JILsMKOM9qzbOiMbLUaXYMRnI7GqhDyyiIfMzfdFW5JQq7Ww3U4HSrlvazBYxG4wsgfKjnpjr26/pU7sUnbcracfLVQ5w24HKjORntUOsKkzTT4+dpj0GM5bI4Hsa0VMAEaODhTgSnvnBIP55qnKqhVUYZidysOee30NUc0+5z1/ahTleGBJb2HpVKG5kgBCtgMORXRXkStCxCfPzzjrz0rn7yAhmc8DrTi09GYXfQ2dNvhIAMjIrVjlH3lIP0rhlYo25Tg1sadqQBCOOTwc1E6TjqiozudpbXXyAE0Vi210DIFJ4zRWSjzGimJbxsdvlZGMcdBw1X7Z12lI32ybsgk9CO4/xqOFOc5ycb1GB0z3qeJ2DySA/LkgjGCB6n88/4VoOGjJ4pSHnZgTlcKxcfIDg7mqaKSNLnyZWRrZxvYr/EyhgrZx1yenvToiGLQuBhhllZQML649eKbqkbTsuyRHGwfcXaeAOCMcfWlc642toI0UUqoZY/JDMF3BR7Cs1QBGxiy2Rn6VpJGQw2MXLEFi54wAOhxUSxywuUZFjkZs5b7wyM5Hp/9epe5vTkZ4lMYOR+R4pmoKl/Bt2jHHPv6ir09kxYgR7VxuLYx+VZsivCpVl2joOeSaaZo7Mylja2nCPyOzdM10llatKqmNhnA4IrLIEsZVsMRkjsfwq9pd79nO2UlQO5HH50SuYNuOxauYpIB+8HB4+lVY8O20+vFb7zQ3MW1sYI+tYt3ELaRtvPYY6ZNJK5UcQjY0eBJHzndg4HH6V0S2cTDBXB6ZArA0Rgirk5PrXRW84AyCBz2rJpuRhOszKudCR3cwSASHorHGePU8ViLE7SqoD4LbWP+eldsSrQknuDxWEIIW1aHyw4CL+9Dcgtk7SvoMHp6rnvxrFW3EsQ2jd0m08tFXYOnP0rTlUKgCjJz6cGm2BBTJPTgVafkEgk+9Qkck6jbON17TI7yFw6ruHQgV51cW0+nXSOhaOSJ9wdDhlIPBB9a9mu4lfduwPc1yWsacsqOGBz2NdFK6HGr0Z59dzT6lqEl1eSvNcTPueRjljgAD+WPwrtfDPhXTE8LTeJvEt4sNkkzwWlmoLS306qCAR2hBI3tnJ5UYOM8ybIwTsrA5B4zV1kYQqhd/KBzsLEqCeuB/WuldzRq6sib4gHQf8AhIXj8IC4XSljUFpSf3snJZkU8qnQBW54/AcvMAo27gf8a1XgBc4BYnnpRDpU1yyq0TJ9R0FZzl1LXuqzMmBG3Davzew5rRleeGS1nQS280f3J4yUZW9VYdx7V0en6NFCEJUlu2B3q9cWCSQESJuRTnB6f/WPvUxvczlVicHLGYtzzDK89fWqoyEZpVBJXjPXHbitzVbK4t9sxhzF91Semf8AHkce+axrxDkndnPUMea1toaRlcpn51LY56+1MBwcZOelTSfc9sY+tW/D2njUdVtoZc+UzZZQ4VnUcsFJ43EcAdzgd6ztrZDlJJXZBDEzIpYDB9akuTtKKQuQORW94xt9P0nXr600qa4uLK3kEUb3CBJGIAzuA6YOR+Fc4qyXUhKjOerdhQ1Z2Ji+ZXRA0Zlfagyxre060W1hwMBj1PrVaxg8olVAMh4ORyau4zgsSp9D1P0qJM2jC2rH5ZlZsfSpI5nj4ZNyt92lhZUPzAsD8vIzircUMc0QIO5Q3O3qAKh6lN2IZI4njbeD0yNozj61bBVOPNCoDkBf4W68/pSASZxMCVdmGccZ7fypZkjeNwI8Z4PpkD1+lNHPJkMbA25CqGLLnAH05+v+FRXJlVYtpG7cCBjGBnOM/nzUkTt8gk3EtlsggZPJNPuGRkYhyQq5XIz05JpmM2ilMpeUxorMWx39e1ZmqQg7kA27Rnb1xWnK+JlkQADcNufz/PgVl3kgWMtuO7mhmC3MKRdp5qM8HPTHers8eQTtwM1TIxW0HdCnHqWrO7eOVQ7HHSiqZ60VXs4vVkqq1o9TvclUKgDevHoD9e//AOqpCpNuoK9Qu75uQff6Y/lVeMjzkBILBc47e5/OrW8kurqNp5B9xn/OK5TriXYiAwZjjI3BicDAOakeQlhs+UsVbcehz29//rVQ3q0GSckgjHYkdf8AGpy0izxkYdUGxgx7Dp7Ac/rUM6U7IuN5YlYuoPViM5JIH8v8aow5LOrMAQQ4x1J9PyNWjGJHDAnGTweApPpVlsLGWIZpBkHgc8Zzmk2aRfQrSXBZHZkU+WuQFbJz9azdSRp44pN2ScDjt7AdhWhexxtbLEgY85c9CD24p6KF8oOqMowDkde5o8jaLMCKGRJQQoYjnd0H0plxuSJIiqqv393Vj9f8K1Zg24sFUK5yp9v896q3UDABQC0rruAbkt71SYNFOLzIAphmIbqVJyKZNeySSASKCRycc/j7UssO9g/mqq45PamLEc7h1bjGe1GnQylTT3Nmx1KJeGkVSOMNxiteHWraM/PcRjHQA1xBBknZRhgOfqauCJVPOMDuKFAxdI7caxbbABPHnPGHFQW12huZGV1JJAGD1rjFhH3mC7ifypuI2kbygyKOD65qrEOieuWt0oQAfj6fWra3K5xv2j19q8it7+9tV+S4fAPRjkfrV628RX3yLIsbgdc8VHKzJ0WelefG80YIDBiAcnGayyoc46g+tci3inYMSWrBQOSG71JF4lhDANDMPfANXBtMzdKXY1tfs4o7GOSGH5wGM5PcqeGB7cHGK5zTXS+QPbKxT1PHer1/4mtZLCaEpL5j7gDt4wQP6isTw1qUFhp0cFwW84ZLHBPU5/lW3Nca54q1jrYNKt2a4kAeSNFXYdmBkkD5v1q3FCv2j5QoA3dB7E1QfxNpCabaRwfaFuvMc3QblJFypj2jsR84P1FVLnxTZC8mZfOwxbaNnY1m5asOWT3OiiQBVGBxkZ6VeNgG0hroNnLYKjnAHrXBv4tgXhIZm59QBTk8Y6jDDKtrDCqP/wA9Mtj/AOvRKUvshGlK+qF16QRxKrlnj80MI8nBbp0H5cVyd7E7MXVGjDZO3njn3rZsb68e8iuY7mSK5gbeksbbWjb1BHQ+hpJLS3IzJC7D+8W5P/6615tDaFOSOYKrnEjZwOFzU8fnqBLB8g6Aq2D9K1J7K2QNJAp28ABhUaxRqsjKMOvTHHeouacvcqfZ5ZX3zhm5ydx6n3rQKB48REIpPOOgp85DJG24DIG7HaobTMdwcgPu42kYDD+lS5GqjYmFoiMTucMvHIwd3+e9Tn98A8zEY4Bx39/r61ObZMFs8BT8uefrmljYeUAq4KxlSMfezjn/AOt7VHMPZDPIG3a5IQtg889OtPSNoJBCCwVQAXHPHXH605BhNkw3oigFj6kDAqfyyI435Bdj8p+vt7fypXMpSFkDCQgNkOcDbx7fXpUc2fubiIzw/NLOxVXYxsV8wEJGC79zwO9Ryz7rhXOVZxnYx9+mfoKtbGLY2RNzSFssw5YkYxjv+o596iJHlhgM5Jzx1pTJmeTZkqRwSc7cjpjvjtTTsfaz7QD39x3NJGcmVLknMhxwrc85H5Vm3Tb2CMQAuenPFXLqQkKMYIJzz1BqjPyxLdOh4oM0RMv7kKDljzVGYYbGOelX7j+EgZ78VSuTkKT1rWmEtivt+YZ70U91AIz+tFd9CMJJ81vm7HPJNPQ7QEKhkwSQNuR1PvU4O23KgrlDuH0+lQoR9nRVzjkZZc5PGPwqSHmPachRnBHevKbO+KGTBtkYRiCR1I4960rZ92cZdmPzNnqOwNZtySrkkA/KWAznI61Lp80hhkPQsecHkD/JqWbRRoxTkynIwd5A69Mf5zVucr5czSEA8FcDGT7fpVdAQNzfcUk4Bwcd+v1qScHc7NgL6A5HpUtmsSJJiMMwzuweOx9/0qYSBlRAu1DlXJ749Kr7gsLrGjL67uo+lTQq0kRU7Y+gyBmpuzREFwrKoBX/AFZ+UEf56057eNFO4tvdcM4PP0q8sYzksdwIA/2jUYVVUAkFVzlsdTmi5orMw7q2MigxrtXjapOcVnz+aquEY8Z59+hzW4fMeV1JYzH5m9KgVI3TYyEOeMnoBVXFY52EsCQFz25qzk+UVBOc8YrSa0Xzvk4RR3HP+TVY25LuRkDOOeKfMLlESRSMLwO/+NJFGFQbSRnmjaqjbwOPvetP7g8YHai4lAinjOcKDg9qTy2VwDwDVkjBGaWUhjwAGouN0ypPHmFwWGcd6j8nainJyOtXnCtFhj1NG1VXGO1PmD2RmtbMcnPBp2nwo0RBPz9K0WXagY4xmkhUR5AA6/lTUhOmQPHujCn5j29KpXUMjIWX5XHpWrGwRpFxknnmhhwGIGWzT5ridMpJZIbZZAhwQPmPrU0UKqBkHA4IqWJmRNhPyg4A9KMZfcCfQ+9LmEqdgVUhnV4VIU9cmphG0zMqDlQcJnqPaoJDkjGB0p0Rx865+U9FPIqlKw3EjPllcMHUeuMkEVDG0Y2EgnBxnPWpruUy58xj5zc+ze/1psW4qiH7gOSvpQ5CsEZePzYCm1s4fI6c8fTrU8ECptkYblBy2089easRW4kWUrncwBycYznmptgSJwWABJ3ZHCnp/SobuCBnEJuY51OQoKEcjrk/pUQGZiTlXZQp9Cc8Y/LNSOpJUkZ+XhkIOSO9OjiLLGFGQGJY4yD3FSSxoiMjMSoALbm/HipV3BC6l9qHamW565wKN2wQ5DDc2M4zx3yKcknydfl5xxwDn/8AXVJmMhJcjd98AEZUds981nOrK6SFtsgPDHnHPr2q1KxVHySQWJx17dfeqN5Ii7VJUhVz93rn/IqrmTHRHfLyyrkjOfTPGKZOm0YjbguSSO+R/I01JAAHiQMxb7o4OPQVHcz8McEYOMYI4NUtEZMp6jLsAbPOOD/SqUhbYoA5zjB4qaTc8hBydxBPGf8AOaiVvmG7JUcc9+aESQ78lhzhTiqk7c49KtMdrSHb1PH+TVOU7nLVrBEy2EYliAeaKbzxRXdQgmndN+n/AAzMJbna21wUMb7SAx5wffGakgzHMynKpvOHYnnJqKJd0e4ZAAJP4dsUBjk7B948Annp/wDWryrnciUODNvcuwyWZc/56VLChikQKQd55/MZPtUMmeWiHReQB368/rUlqrKzRMnzk4Ge+Of8+1S2axZoh/KgBIVW7n8en1p43Sx8AABcHdxwDnn86gMf7nuHOCMk8VMvCyISNxAHI9ecfrWZvEd5qLjkFsjGPT8asIRjauN23Bz2wf51VCATOiAMwXnP9KcOGIiTBPAPXtyaVzQnjMvmBdwABwQ3BHvT4l2yORwRkLk5y3uKhg/1bEqcgnk/xehqwT93kFh835+tTexRAUZJC3QfxHoSTTDD5Zwud+7gntVhowMZXcrYPzHpUakiQMuQpJyMfhTuA3G2Fh8vmSMMk9qiuY18tIxgFvarUyBtiqQFHUe9OjQL9/GcY+lFyrmbFpO+NpHAyzDHsKnm0sRn5MPngdq0kLIoB/h5wep96fDl2V5MEkg9P0p3Gmc19gcZbqR3xTBbne7HJxxXcZjUIpjDbAeMckn+dVI44JHl2Rr5YO4rj7340XLTOXtbfawaRNyYps8BReRxn0rure1spBGH2ogQsF7sfSsvWYrdI5AmzcxAULzg1RUZq9jmDASgJGMnGPWomg2SHJPJ9a7U6I7wRSDaQDynQjj1qve6EEs5ZgFLbgOTyKYXi3Y5Yw4ceW4OQcnGKRocR5By2cYxW7NpoRoFONzNgj1zU0Ngu2ZAATkHa2D0NILI5homD5xjPWmpGWO0LxXW3FnB5oCohz1HSqE0EKMxXkZ4wKLmejOeeMsjZGQODSxQk429DggitxLNSxZAV3L39ajggjWJsEEgH+fahMloy2gYukbkEMeParMVsdi44YtkFujetT+WrNvGMkjDD+E0NxtHQLwnHXFFzJvsJlEV+cYG4DOMZ/8A1U1Pmj34VlyCcdTRnPB4XGFyPanWzFY1UYyhwP5HNK5NwSLaASuFdSc5461Gz7w20nqScn8v5VPkOc/MdzBUC1EUYOxIJKkKwIHA/wA9qLkMWMYUgAkIu5mI5x7elSGPKI5O1QmFUjr3yah37WYMMg4wMdsdP1qTKbYsnbGCVwWyRnp+tNMhle6YjO1gA5I4659PzH61nXhEZYMRw2NuO/8AkVouwaNehLHqec9uv4VlXKO8hduVA3E+gyMf5960RjJiwsGEfmZBA3EsearXEri4kY5Cnnb16dDVifaryrGQU5CnsciqF1zKFwu4csM/oD6c1aRk2K4ATafl3Ee+KqyZJIzxjG4fWnb/ALxXJx+ZqDJaVlHIXofeqSJ2EZgJGTAJx27VSk4YirkaAICeG5/GqUnXPatYEz2Gk9MGik6nFFdFPmt7qMGzs45NiMp+XjA9zj/GnxbC3zh1KgNgf3v8OtQnb5SMgIJJ+Y9Md6kt3PzFX6DI7gDJ/nXmncmXc4DmNmJbBUc5b/GmNMBOspVhuAOccE9Dj0GKaJCWygJUDcDnnIOcUlzGEUhNueXUD+HPOKTNC9BIZGjZ9wwvPofTAq0HJkxwQ+HJxk5HQflVSBtkcbJguFX5S3BGcYH51Kqnydwxxx8vHOfWs2bRZYZsBpFzuJBbIxx2py/Kik7mzkbsZJ9cVArKH3nJJx1PpxUrSKiBBy24ZHuak2THoGTd82B0UnsafECnLD5eBx7Uj4YKQnzgEEn+VELMPMDKSG+6AOlItCsVLAMpwRuJPH4UicEeYWDZyOO1RyEq5Dcx/dHHA9aUu7LuUDahA9+tFxkrLuQp0C/dJ7+9MLbdqgnocMadKqyAndtwQeex/wAKikwBG/LZO3NCJuX7ZGnaNom564bvTVkaMKwbueMdDVSzlyxC5Cqw/A1fiRUd8nl+5H6Ux81hxmBRlZgC3G40sLRGLa6uGAyMHiq6BWBO9Ayj7rHinO+1w3C4w2T/AEqkrg5ks04j2ogJOeCB0qteSK4UeUoAOTtpsbtLGZlJ2ZJOR1qO4kEil9ijGNqZ4p2GqiNm3vm8sLGzfMw3K3Sob2eZlHzt5WeeKzod0h5jCkHnmrBl8vgcgfdBPFNoamtyC7vC00BcsFQ5wg6UyK//ANJHOFwcA8E+pqC6kbcztKuPTHBz6VHcfIwxt3HjJGfwpWE6i2Lkt2DKuXjXI/hGTVd5gVKquG7/AEqJJHefYAqluAccCrMEZWZCAGAJ3E9Kl3FzXJosxAAnnaMiq00oXCIAc5BPYCp5ZVYNwxUk4wMdKoNsMa/NhTyfegTlYefLji2xnC9cD1puAIlVcljnOecDvULkKwGNx7Y7Chpf48EBeCD3Bpmd7g8ucKw3cYFRYKHHBcAk+hpCTgEfefpxn2pw+VmdwMkY9SfYUibj4HIKsNzRoOCozgev506eQ4Vt25tn3Rx05OaTcId/UY5PGO4zRKhK7ABgMSGzwRj/AAoExSQQeSEIB6eg/So2aJY1ZiuAMjIJDH/P8qlxkHD5UZx9CB3/AAqG4YFX2cKozgj8qohlaZ8wqo29cj0/L0pjhVjPnKQSdgHX07/lSySFXZmI4yhB7Dr1/wAKbLCxz5hA2kEAe9axMWU2KNMyAMsaN09eP8agvHDy5G5i5O44ycf571Lcbd7MR97AyefaqD5jmZcqoKkAHjFWjFjGO0ttB54wOmP/AK3ekUMxA4HrzTTtEvl7uO/49aWVgIQF5x97j37VRNyKXKk7s4PQ1Uk9DVqQmQgsRtxiqsvLEjoK0gKWwxTgiikx+JorrpSlFOxg3Y7AgnYrqAHBI9Mj/wCvRbLsUk5O7uD/ACpFcZZX+7nqfpmkj2o+WBOWI56k15djtTLwLK2Vzz0wMZxTdxYSxpt+9we/4f55oRnLKRu+UYbjin7NgDptB3Dn0FSzVD0neMDaQdh28enOafbgbVCgrweScZ/Co5gxRtodQCDnjiiAssJ3HJU84PvmoZpEvIRIikjAGAB3ye9PAAJfOAn8R7ntVVM8jLKTyAe30qym5U5B+bqKhm6Hxr3cksCT8ppZJC0hJQhScIc0rgliEYDnJI9u1PhIICn5QvXjv3pGiQ6JZNquQPm52nsakXLbVAypPGT27ipYkDRsARkE7iTn6VEzLHESFJIwAfQntSKRLDtaVhgAZwMjsOtP8tCABwSM8n+lMVN0iNn5RyOeuetSSASYB2+YvUZ6ikJoqNGpBG7Dg84GMmiRzCkrAMVP8J5omQeZ8ity3I9OKSE/KVHQscg1SYpRCRsFSEBj6k+2KpSHc4RzwPmU98dqnMcvzo7cE4OD2/xpFRADHJCzqv3W6FsVrEwk7CCUIi7nYnjLL0+lSRAnGXDOpyeaqxJholT5c5cljnn6VLDCyyFpJI8D0Ge3etUzG7LVyBIV2XG+EDc3bH09aZHIqRuSzCI42bv4aqPMJuQPJjVvlGDwafKMRqXbcT09vwofctNsjnWMkBmyF4yRwalWORsbnUxjnax556VE0ayOrFwyFSTuJ602BZElz5xVpF49h61INu5ct1+zRgbC7yjjH8vpS3ErudjIFcjG1e31qO384oUQkrt+V2459aTZsljbqwGWPXJqS43Elmlb77rheNoHSqzSoYjIoJXaVUYp8ufJVIhkZBYk9fam+WEXJ6j5cA8VI3dkO0rtcry3OPSpQpKxhiA4J+mKe4LxI2CMjr0700owXBX5jkZH9Km4khm0NIXwRkgBT0GKEXHl5+7y3H1ozswMgkLhu/NFohMwDDA2nj8eKTGTSKfLQbcbsOSecj1qKQFvs3zAIVY49eCP6VeUKzwsPmQHPOOmDxVd4yojBBYuRgYPGScdfwoJKoRhGqkqe4wfu45PHvVediqyYPHGVPqPp25qadiYyny9D93r7f4VVlLK+CArFuc1pFGUmBVRKwQbgFLlh+lQy7k3BNxwcnvwe9Pt3IEgAdvMcrxxgDmkdvLB2vlgVGOhrQxb0M+R9rAADGORnr71SnLDIOGZsAEVcuVHmhCFGeWGen+TVGZgyEEj5MdPrVxMyLaPs+SvOc7u2e1EnKA4yT1x2p6oZYmLdzwD6VDGG890PPbHtVoljXwY16gDOOKrt645qwzAhgOg71Xc7iSOM1cRSG9/SijqTiiuimpte6rnPI6m3YkKM8bCfxpYDvLF8EhiASOgoorzWdyL0R3OSe3SrTqFt3YABgAcj8aKKn7JcRV/eK2/nMTE9qhBJ81jySisT7miiplsaomX5QhHUZH6mrLkgHBwQwxiiioOiO5PbHMiZ75zTnJWQAcAmiikzVFiM7JXC8DIqSL5jhgCCxJzRRUh0I4WJiHP8R/nU2ALl+O+KKKTLRFbSObtATkHIquVH2hByAHzgGiiqQpjtTUGPHP3h0OO9WAB5SnuCMfnRRWiOee5XsokmkmMq7irNgntUsUSJLGVUAs3PvRRWsTKRFuJeRD91WBA96bCxEQkz85U80UUNjgRSYxAuBtJORipmYyTBHwVVSAMD0oopLcpjF+WDavAGAPpUjfLdrjj5P50UVLLsQfel5weQKanW6b+JD8p9KKKkp9Bw+YAHoGAFK5O5j3B4ooqSTNJzK6noGFTxgG5UHptH86KKRHQcXZHypwdw/kasT/eVe3m4x+BooqkEtjKPzRsT1AwPpVWf/Ws38RJJPrwaKKuJjU3JTxAmO20fmDUG45X/cz+OcUUVp1MZdTPb5pyG5GSeaoD7w92ycUUVaIWxOCREcdyapoBvmPfdRRTiQRkcuO2CarnjFFFaxImD8E49aKKKuM5R+F2Mmj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gingiva appears purple with infiltration. Disfiguing nodular KS lesions are also present on the adjoining area of the hard palate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds), Williams and Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3008=[""].join("\n");
var outline_f2_60_3008=null;
var title_f2_60_3009="Capnocytophaga peripheral smear";
var content_f2_60_3009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Capnocytophaga canimorsus, a potential emerging microorganism in splenectomized patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 48-year-old splenectomized patient who had recent dog exposure was admitted with respiratory failure. The peripheral blood film was reviewed and showed the presence of bacteria within the neutrophils (note their characteristic filamentous rod-shape morphology). Blood culture and further sequencing of DNA confirmed the microorganism as Capnocytophaga canimorsus, part of the normal flora found within the oral cavity of dogs and cats. Subsequent to the diagnosis, the patient developed septic shock and disseminated intravascular coagulation, despite intravenous antibiotics administration, and died within a few days of commencing treatment. This case illustrates the importance of urgent screening of peripheral blood films for bacteria, especially in septic asplenic patients who have a history of domestic animal exposure. In addition, this group of patients should be given oral penicillin for prophylaxis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yu, RK, Shepherd, LE, Rapson, DA. Images in Haematology. British J Haematology 2000; 109:679. Copyright &copy; 2000 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3009=[""].join("\n");
var outline_f2_60_3009=null;
var title_f2_60_3010="Hysterosc microins in tube";
var content_f2_60_3010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopic sterilization microinsert: Placement and tissue infiltration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Essure. Copyright &copy;2009 Conceptus, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3010=[""].join("\n");
var outline_f2_60_3010=null;
var title_f2_60_3011="Prune belly syndrome";
var content_f2_60_3011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Prune belly syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two patients with the prune belly syndrome with lack of abdominal musculature.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3011=[""].join("\n");
var outline_f2_60_3011=null;
var title_f2_60_3012="Tazarotene: Pediatric drug information";
var content_f2_60_3012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tazarotene: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"    see \"Tazarotene: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/32/26116?source=see_link\">",
"    see \"Tazarotene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avage&reg;;",
"     </li>",
"     <li>",
"      Tazorac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tazorac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Keratolytic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"      see \"Tazarotene: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne vulgaris:",
"     </b>",
"     Children &ge;12 years, Adolescents, and Adults: Topical: Tazorac&reg; (0.1% cream or gel): Apply as a thin film (2 mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     ) to affected areas once daily in the evening for up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cream: Adolescents &ge;18 years and Adults: Topical: Tazorac&reg; (0.05%): Initial: Apply a thin film (2 mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     ) to affected area once daily in the evening; may increase strength to 0.1% if tolerated and necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel: Children &ge;12 years, Adolescents, and Adults: Topical: Tazorac&reg; (0.05%): Initial: Apply a thin film (2 mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     ) to affected area once daily in the evening for up to 12 months; may increase strength to 0.1% if tolerated and necessary; apply to no more than 20% of the body surface area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines:",
"     </b>",
"     Adolescents &ge;17 years and Adults: Avage&reg;: Apply a pea-sized amount once daily at bedtime; lightly cover entire face including eyelids if desired",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avage&reg;: 0.1% (30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazorac&reg;: 0.05% (30 g, 60 g); 0.1% (30 g, 60 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazorac&reg;: 0.05% (30 g, 100 g); 0.1% (30 g, 100 g) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes and mouth; also avoid contact with the eyelids when used for acne or psoriasis. Do not apply to eczematous or sunburned skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acne: Apply in evening after gently cleansing and drying face; apply enough to cover entire affected area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines: Apply to clean, dry face at bedtime; lightly cover entire face including eyelids if desired. Emollients or moisturizers may be applied before or after; if applied before tazarotene, ensure cream or lotion has absorbed into the skin and has dried completely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Psoriasis: Apply in evening. If a bath or shower is taken prior to application, dry the skin before applying. If emollients are used, apply them at least 1 hour prior to application. Unaffected skin may be more susceptible to irritation; avoid application to these areas.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Store at 25&deg;C (77&deg;F); excursions permitted to -5&deg;C to 30&deg;C (23&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Treatment of acne vulgaris [Tazorac&reg; (0.1%): FDA approved in ages &ge;12 years and adults]; treatment of plaque psoriasis [Tazorac&reg; (0.05% and 0.1%): FDA approved in ages &ge;18 years and adults]; mitigation (palliation) of facial skin wrinkling, facial mottled hyper-/hypopigmentation, and benign facial lentigines as adjunct to comprehensive skin care and sunlight avoidance [Avage&reg; (0.1%): FDA approved in ages &ge;17 years and adults]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: Treatment of mild to moderate facial acne vulgaris [Tazorac&reg; (0.1%): FDA approved in ages &ge;12 years and adults]; treatment of stable plaque psoriasis of up to 20% body surface area involvement [Tazorac&reg; (0.05% and 0.1%): FDA approved in ages &ge;12 years and adults]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F224867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning/stinging, cheilitis, contact dermatitis, desquamation, discoloration, dry skin, eczema, erythema, fissuring, inflammation, irritation, localized bleeding, photosensitization, pruritus, rash, skin pain, worsening of psoriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Blistering",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tazarotene, other retinoids, vitamin A derivatives (eg, isotretinoin, tretinoin), or any component; pregnancy; use in women of childbearing potential who are unable to comply with birth control requirements",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes and mouth; also avoid contact with the eyelids when used for acne or psoriasis. Not for use on eczematous, broken, or sunburned skin; may cause severe irritation. Treatment with tazarotene may increase skin sensitivity to weather extremes of wind or cold; concomitant topical medications (eg, medicated or abrasive soaps, cleansers, or cosmetics with a strong drying effect) should be used with caution due to increased skin irritation. Should not be used to treat lentigo maligna. Avoid application over extensive areas; specifically, safety and efficacy of gel applied over &gt;20% of BSA have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Women of childbearing potential must use adequate birth control measures; a negative pregnancy test within 2 weeks prior to beginning treatment is recommended; begin treatment during a normal menstrual period. Tazarotene may cause photosensitivity; exposure to sunlight (including sunlamps) should be avoided unless deemed medically necessary, and in such cases, exposure should be minimized (including use of sunscreens/protective clothing). Risk may be increased by concurrent therapy with known photosensitizers (thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm if administered to a pregnant woman. A negative pregnancy test should be obtained within 2 weeks prior to treatment; treatment should begin during a normal menstrual period.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disease severity in plaque psoriasis (reduction in erythema, scaling, induration); pregnancy test prior to treatment of females of childbearing age",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic, acetylenic retinoid which modulates differentiation and proliferation of epithelial tissue and exerts some degree of anti-inflammatory and immunological activity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Psoriasis: 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Psoriasis: Up to 12 weeks after discontinuation when initially treated for 2-3 months (duration may be less if initial treatment was shorter)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal following cutaneous application (&le;6% of dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Metabolite: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug, rapidly metabolized via esterases to an active metabolite (tazarotenic acid) following topical application and systemic absorption; tazarotenic acid undergoes further hepatic metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Metabolite: 18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine and feces as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/32/26116?source=see_link\">",
"      see \"Tazarotene: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes and mouth; also avoid contact with the eyelids when used for acne or psoriasis. Severe skin reactions may occur; do not use on eczematous, broken, or sunburned skin. Avoid washing face more frequently than 2-3 times per day; avoid using topical preparations with high alcoholic content during treatment period.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if redness or discoloration, irritation, burning, stinging, excessive dryness, or worsening of condition occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13004 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3012=[""].join("\n");
var outline_f2_60_3012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224841\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050155\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050148\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224820\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224805\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050158\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050151\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050157\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224867\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050162\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050147\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050146\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300105\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224814\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224816\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224828\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050154\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050145\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050160\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050161\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050153\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=related_link\">",
"      Tazarotene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/32/26116?source=related_link\">",
"      Tazarotene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_60_3013="Pterygium 2 and 3";
var content_f2_60_3013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examples of pterygium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J. Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3013=[""].join("\n");
var outline_f2_60_3013=null;
var title_f2_60_3014="Contents: Cardiac arrhythmias";
var content_f2_60_3014=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cardiac arrhythmias",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cardiac arrhythmias",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ablation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/60/15304\">",
"           Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13129\">",
"           Catheter ablation for ventricular arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33431\">",
"           Catheter ablation of atrial tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/25/19866\">",
"           Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10853\">",
"           Concealed accessory pathways",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24408\">",
"           Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/9/22681\">",
"           Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/62/40938\">",
"           Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antiarrhythmic drugs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25065\">",
"           Amiodarone and thyroid dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/4/29767\">",
"           Amiodarone pulmonary toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/24/12682\">",
"           Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20938\">",
"           Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/57/39831\">",
"           Calcium channel blockers in the treatment of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38857\">",
"           Clinical uses of amiodarone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/28/12745\">",
"           Clinical uses of dronedarone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/57/23449\">",
"           Major side effects of amiodarone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/39/3704\">",
"           Major side effects of beta blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/9/37018\">",
"           Major side effects of class I antiarrhythmic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/33/38422\">",
"           Myocardial action potential and action of antiarrhythmic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19143\">",
"           Pulmonary disease induced by cardiovascular drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16217\">",
"           Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/10/28841\">",
"           Therapeutic use and major side effects of sotalol",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/63/28663\">",
"           Therapeutic use of dofetilide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/11/40118\">",
"           Therapeutic use of ibutilide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8711\">",
"           Treatment with digoxin: initial dosing, monitoring, and dose modification",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Atrial fibrillation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20503\">",
"           ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/24/12682\">",
"           Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20938\">",
"           Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1258\">",
"           Anticoagulation in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28602\">",
"           Atrial fibrillation and flutter after cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/34/28199\">",
"           Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24042\">",
"           Atrial fibrillation in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/61/983\">",
"           Cardiac resynchronization therapy in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/28/12745\">",
"           Clinical uses of dronedarone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24408\">",
"           Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/50/12074\">",
"           Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28522\">",
"           Epidemiology of and risk factors for atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/28/6601\">",
"           Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39016\">",
"           Management of new onset atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/50/39721\">",
"           Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12266\">",
"           Mechanisms of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/32/43528\">",
"           Mechanisms of thrombogenesis in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/11/21686\">",
"           Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/34/37418\">",
"           Nonresponse and resistance to clopidogrel",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/361\">",
"           Overview of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6473\">",
"           Overview of the acute management of tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31384\">",
"           Paroxysmal atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/62/40938\">",
"           Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22426\">",
"           Restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/43/5817\">",
"           Rhythm control versus rate control in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/23/27001\">",
"           Risk of embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/50/2856\">",
"           Role of echocardiography in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39383\">",
"           Stroke in patients with atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/14/16615\">",
"           Supraventricular arrhythmias after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/45/37591\">",
"           Surgical approaches to prevent recurrent atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26278\">",
"           The electrocardiogram in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/15/5367\">",
"           The role of pacemakers in the prevention of atrial fibrillation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Atrial flutter",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28602\">",
"           Atrial fibrillation and flutter after cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36228\">",
"           Atrial flutter: Epidemiology, classification, and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/57/18328\">",
"           Control of ventricular rate in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/53/15192\">",
"           Electrocardiographic and electrophysiologic features of type I atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12165\">",
"           Electrocardiographic and electrophysiologic features of type II atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/40/37511\">",
"           Embolic risk and the role of anticoagulation in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24888\">",
"           Maintenance of sinus rhythm after cardioversion in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/60/13256\">",
"           Overview of the evaluation and management of atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/49/18201\">",
"           Restoration of sinus rhythm in atrial flutter",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Atrial tachycardia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21864\">",
"           Focal atrial tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/9/9368\">",
"           Intraatrial reentrant tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/20/38216\">",
"           Multifocal atrial tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6473\">",
"           Overview of the acute management of tachyarrhythmias",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Conduction disturbances",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4282\">",
"           Conduction abnormalities after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10376\">",
"           Congenital third degree (complete) atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12261\">",
"           Course and treatment of chronic bifascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/5/4184\">",
"           Electrocardiographic abnormalities and conduction disturbances in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/16/32007\">",
"           Etiology of atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/38/41574\">",
"           First degree atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16886\">",
"           Left anterior fascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/54/39784\">",
"           Left bundle branch block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40723\">",
"           Left median (middle or septal) fascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/2/16420\">",
"           Left posterior fascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10344\">",
"           Right bundle branch block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18087\">",
"           Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/62/998\">",
"           Second degree atrioventricular block: Mobitz type II",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15285\">",
"           Third degree (complete) atrioventricular block",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/19/31034\">",
"           Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39481\">",
"           Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/53/15192\">",
"           Electrocardiographic and electrophysiologic features of type I atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12165\">",
"           Electrocardiographic and electrophysiologic features of type II atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12266\">",
"           Mechanisms of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/8/43144\">",
"           Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26278\">",
"           The electrocardiogram in atrial fibrillation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Electrophysiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6614\">",
"           Anatomy and electrophysiology of the sinoatrial node",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/21/39256\">",
"           Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/53/15192\">",
"           Electrocardiographic and electrophysiologic features of type I atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12165\">",
"           Electrocardiographic and electrophysiologic features of type II atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24025\">",
"           Electrophysiologic evaluation of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/61/13271\">",
"           General principles of asynchronous activation and preexcitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/51/22328\">",
"           Invasive cardiac electrophysiology studies: Bradyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3097\">",
"           Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12266\">",
"           Mechanisms of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/33/38422\">",
"           Myocardial action potential and action of antiarrhythmic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/2/12326\">",
"           Overview of invasive cardiac electrophysiology studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/62/42984\">",
"           Reentry and the development of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26278\">",
"           The electrocardiogram in atrial fibrillation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/41/23192\">",
"           Arrhythmia in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/1/23576\">",
"           Arrhythmias following cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/19/17719\">",
"           Arrhythmic complications of mitral valve prolapse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36228\">",
"           Atrial flutter: Epidemiology, classification, and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28072\">",
"           Basic approach to arrhythmias due to digoxin toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/33/23062\">",
"           Cardiovascular effects of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/10/30890\">",
"           Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/5/42070\">",
"           Enhanced cardiac automaticity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28522\">",
"           Epidemiology of and risk factors for atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22008\">",
"           Manifestations and causes of the sick sinus syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/54/16233\">",
"           Pathophysiology and etiology of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/62/42984\">",
"           Reentry and the development of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/36/13898\">",
"           Risk of sudden cardiac death in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/14/16615\">",
"           Supraventricular arrhythmias after myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/32/36361\">",
"           Ambulatory monitoring in the assessment of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/18/4391\">",
"           Clinical applications of the signal-averaged electrocardiogram: Overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/54/9064\">",
"           Diagnosis and evaluation of the sick sinus syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39289\">",
"           Electrophysiologic cardiac mapping: Techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/42/27305\">",
"           Electrophysiologic cardiac mapping: Use in specific arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24025\">",
"           Electrophysiologic evaluation of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/40/37511\">",
"           Embolic risk and the role of anticoagulation in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4490\">",
"           Evaluation of the survivor of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/10/4264\">",
"           Heart rate variability: Technical aspects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10601\">",
"           Heart rate variability: Use after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/39/35449\">",
"           Heart rate variability: Uses other than after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/51/22328\">",
"           Invasive cardiac electrophysiology studies: Bradyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3097\">",
"           Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/2/12326\">",
"           Overview of invasive cardiac electrophysiology studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/33/10778\">",
"           QT dispersion: Clinical applications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/51/26425\">",
"           QT dispersion: Measurement and interpretation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/50/2856\">",
"           Role of echocardiography in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/8/43144\">",
"           Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/50/13093\">",
"           Technical aspects of the signal-averaged electrocardiogram",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/39/10872\">",
"           Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27544\">",
"           Use of the signal-averaged electrocardiogram in ischemic heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/51/36661\">",
"           Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/46/21224\">",
"           Vagal maneuvers",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Implantable devices",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/56/11142\">",
"           Cardiac device interactions with electromagnetic fields",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/12/30921\">",
"           Cardiac implantable electronic device lead removal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/17/11545\">",
"           Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/56/18314\">",
"           Cardiac resynchronization therapy in heart failure: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/20/30024\">",
"           Driving restrictions in patients with an implantable cardioverter-defibrillator",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31302\">",
"           Dual chamber pacing system malfunction: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/50/24362\">",
"           General principles of the implantable cardioverter-defibrillator",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19657\">",
"           Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30599\">",
"           Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/19/5434\">",
"           Implantable cardioverter-defibrillators: Complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39672\">",
"           Implantable cardioverter-defibrillators: Patient follow-up",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/52/27463\">",
"           Indications for permanent cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44345\">",
"           Infections involving cardiac implantable electronic devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1849\">",
"           Modes of cardiac pacing: Nomenclature and selection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31510\">",
"           Overview of cardiac pacing in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/14/21737\">",
"           Pacing system malfunction: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/23/43385\">",
"           Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/61/21465\">",
"           Temporary cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38295\">",
"           Unexpected rhythms with normally functioning Dual-Chamber Pacing Systems",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/15/36088\">",
"           Wearable cardioverter-defibrillator",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Long QT syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/55/23418\">",
"           Acquired long QT syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/9/2202\">",
"           Clinical features of congenital long QT syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/6/33897\">",
"           Diagnosis of congenital long QT syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/0/28681\">",
"           Genetics of congenital and acquired long QT syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/23/9591\">",
"           Pathophysiology of the long QT syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/3/26682\">",
"           Prognosis and management of congenital long QT syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/42/16042\">",
"           High altitude, air travel, and heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27097\">",
"           Tachycardia-mediated cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preexcitation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/21/39256\">",
"           Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/47/24311\">",
"           Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24025\">",
"           Electrophysiologic evaluation of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/61/17370\">",
"           Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/61/13271\">",
"           General principles of asynchronous activation and preexcitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/0/11272\">",
"           Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17943\">",
"           Mahaim fiber tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/9/22681\">",
"           Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/60/15305\">",
"           Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sinus node",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6614\">",
"           Anatomy and electrophysiology of the sinoatrial node",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/54/9064\">",
"           Diagnosis and evaluation of the sick sinus syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22008\">",
"           Manifestations and causes of the sick sinus syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/2/2086\">",
"           Normal sinus rhythm and sinus arrhythmia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/54/38756\">",
"           Sinoatrial nodal pause, arrest, and exit block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/23/34166\">",
"           Sinoatrial nodal reentrant tachycardia (SANRT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/50/3878\">",
"           Sinus bradycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/25/14742\">",
"           Sinus tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/44/37576\">",
"           Treatment of the sick sinus syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sudden cardiac death",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/33/13850\">",
"           Advanced cardiac life support (ACLS) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/39/25208\">",
"           Automated external defibrillators",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28250\">",
"           Brugada syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/52/12101\">",
"           Commotio cordis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11288\">",
"           Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4490\">",
"           Evaluation of the survivor of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/24/20874\">",
"           Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/21/30041\">",
"           Outcome of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/55/890\">",
"           Overview of sudden cardiac arrest and sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/46/28394\">",
"           Overview of the benefits and risks of exercise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/54/16233\">",
"           Pathophysiology and etiology of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/23/3448\">",
"           Pharmacologic therapy in survivors of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/15/23800\">",
"           Psychosocial factors in sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/36/13898\">",
"           Risk of sudden cardiac death in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/62/15338\">",
"           Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/23/43385\">",
"           Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/37/31318\">",
"           Screening to prevent sudden cardiac death in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/61/19417\">",
"           Short QT syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/12/15559\">",
"           Sudden cardiac arrest in the absence of apparent structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/24/8585\">",
"           Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/36/15945\">",
"           Treatment and prevention of sudden cardiac arrest in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22586\">",
"           Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/15/36088\">",
"           Wearable cardioverter-defibrillator",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Supraventricular tachycardia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/52/17226\">",
"           Atrial arrhythmias (including AV block) in congenital heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24793\">",
"           Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/60/15304\">",
"           Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10853\">",
"           Concealed accessory pathways",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37030\">",
"           Maternal conduction disorders and bradycardia during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6473\">",
"           Overview of the acute management of tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/23/34166\">",
"           Sinoatrial nodal reentrant tachycardia (SANRT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/1/14362\">",
"           Supraventricular arrhythmias during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/27/441\">",
"           Supraventricular premature beats",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Syncope",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10598\">",
"           Carotid sinus hypersensitivity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/15/18682\">",
"           Evaluation of syncope in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/11/28855\">",
"           Management of the patient with syncope",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/9/5272\">",
"           Pathogenesis and etiology of syncope",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/0/18442\">",
"           Reflex syncope",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27399\">",
"           Upright tilt table testing in the evaluation of syncope",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/24/12682\">",
"           Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20938\">",
"           Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33223\">",
"           Arrhythmia management for the primary care clinician",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24042\">",
"           Atrial fibrillation in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/35/17977\">",
"           Basic principles and technique of cardioversion and defibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/57/39831\">",
"           Calcium channel blockers in the treatment of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11050\">",
"           Cardioversion for specific arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/60/15304\">",
"           Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13129\">",
"           Catheter ablation for ventricular arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33431\">",
"           Catheter ablation of atrial tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/36/36424\">",
"           Clinical significance and treatment of ventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38857\">",
"           Clinical uses of amiodarone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10853\">",
"           Concealed accessory pathways",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24408\">",
"           Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/50/12074\">",
"           Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/57/18328\">",
"           Control of ventricular rate in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12261\">",
"           Course and treatment of chronic bifascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/40/37511\">",
"           Embolic risk and the role of anticoagulation in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/50/24362\">",
"           General principles of the implantable cardioverter-defibrillator",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19657\">",
"           Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30599\">",
"           Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39672\">",
"           Implantable cardioverter-defibrillators: Patient follow-up",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/52/27463\">",
"           Indications for permanent cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24888\">",
"           Maintenance of sinus rhythm after cardioversion in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39016\">",
"           Management of new onset atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22952\">",
"           Management of nonsustained ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1849\">",
"           Modes of cardiac pacing: Nomenclature and selection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/9/22681\">",
"           Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/361\">",
"           Overview of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/23/3448\">",
"           Pharmacologic therapy in survivors of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/60/15305\">",
"           Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/3/26682\">",
"           Prognosis and management of congenital long QT syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/62/40938\">",
"           Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22426\">",
"           Restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/49/18201\">",
"           Restoration of sinus rhythm in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19322\">",
"           Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/24/8585\">",
"           Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/44/34503\">",
"           Surgery for ventricular tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/45/37591\">",
"           Surgical approaches to prevent recurrent atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/10/28841\">",
"           Therapeutic use and major side effects of sotalol",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/63/28663\">",
"           Therapeutic use of dofetilide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/11/40118\">",
"           Therapeutic use of ibutilide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/47/21241\">",
"           Ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/15/36088\">",
"           Wearable cardioverter-defibrillator",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ventricular arrhythmia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13129\">",
"           Catheter ablation for ventricular arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/10/30890\">",
"           Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/36/36424\">",
"           Clinical significance and treatment of ventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/38/38505\">",
"           Early repolarization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/23/376\">",
"           Electrical storm and incessant ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/23/1401\">",
"           Left ventricular hypertrophy and arrhythmia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/23/5497\">",
"           Left ventricular thrombus after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/17/14615\">",
"           Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/17/12570\">",
"           Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/6/9320\">",
"           Prevalence and evaluation of ventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/38/31336\">",
"           Prophylaxis against ventricular arrhythmias following myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16217\">",
"           Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19322\">",
"           Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/44/34503\">",
"           Surgery for ventricular tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22586\">",
"           Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/31/7674\">",
"           Ventricular arrhythmias during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/47/21241\">",
"           Ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/15/36088\">",
"           Wearable cardioverter-defibrillator",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ventricular tachycardia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/42/41637\">",
"           Bundle branch reentrant ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/48/37641\">",
"           Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22952\">",
"           Management of nonsustained ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/14/26858\">",
"           Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/41/13974\">",
"           Nonsustained VT in the absence of apparent structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6473\">",
"           Overview of the acute management of tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/17/12570\">",
"           Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/49/39702\">",
"           Prognosis of nonsustained VT in the presence of structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/32/29193\">",
"           Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22586\">",
"           Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/15/36088\">",
"           Wearable cardioverter-defibrillator",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-50FF126A74-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f2_60_3014=[""].join("\n");
var outline_f2_60_3014=null;
var title_f2_60_3015="Treatment of Takayasu arteritis";
var content_f2_60_3015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Takayasu arteritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/60/3015/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/60/3015/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/60/3015/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/60/3015/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/60/3015/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/60/3015/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/60/3015/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Takayasu arteritis is a chronic vasculitis of unknown etiology. Women are affected in 80 to 90 percent of cases, with an age of onset that is usually between 10 and 40 years.",
"   </p>",
"   <p>",
"    Takayasu arteritis primarily affects the aorta and its primary branches (",
"    <a class=\"graphic graphic_table graphicRef62022 \" href=\"UTD.htm?37/7/38011\">",
"     table 1",
"    </a>",
"    ). The initial vascular lesions frequently occur in the left middle or proximal subclavian artery. As the disease progresses, the left common carotid and vertebral, brachiocephalic, right middle or proximal subclavian, right carotid and vertebral arteries, as well as the aorta, may also be affected. The abdominal aorta and pulmonary arteries are involved in approximately 50 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inflammatory processes cause thickening of the walls of the affected arteries. The proximal aorta (eg, aortic root) may become dilated secondary to inflammatory injury. Narrowing, occlusion, or dilation of involved portions of the arteries in varying degrees results in a wide variety of symptoms.",
"   </p>",
"   <p>",
"    The treatment of Takayasu arteritis will be reviewed here. The pathogenesis, pathology, clinical manifestations, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of therapy for Takayasu arteritis is glucocorticoids. Angioplasty or bypass grafts may be necessary once irreversible arterial stenosis has occurred. Treatment of hypertension and heart failure should be instituted if these complications occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids effectively suppress the systemic symptoms and usually arrest progression of Takayasu arteritis. The normochromic anemia and elevated acute phase reactants also return to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/1\">",
"     1",
"    </a>",
"    ]. Arterial stenosis may reverse, and ischemic symptoms may improve in early cases. However, the vascular response is diminished once fibrous tissue has formed in the involved vessels or once thrombosis has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Initial glucocorticoid dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial daily dose of 45 to 60 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent dose should be started in an adult of average size. A single morning dose is usually effective and convenient. Divided daily doses provide a more continuous antiinflammatory effect but may result in an increased number of adverse reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) Alternate day glucocorticoid doses are generally not as effective as daily therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Assessing response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decrease and eventual disappearance of constitutional symptoms is expected and is typically accompanied by a decrease in acute phase reactants such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.",
"   </p>",
"   <p>",
"    Computerized tomography (CT) or magnetic resonance imaging (MRI) scans can also be used to follow the response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The potential efficacy of this approach was evaluated in 31 patients in whom repeat CT angiography was performed over a median period of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/3\">",
"     3",
"    </a>",
"    ]. Thoracic or abdominal aortic aneurysms were initially noted in 12 patients (approximately 40 percent) and subsequently developed in two during follow-up. Rapidly increasing aneurysmal size (more than 1",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    occurred in three patients despite glucocorticoid therapy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62264 graphicRef70960 \" href=\"UTD.htm?8/59/9144\">",
"     image 1A-B",
"    </a>",
"    ); this was accompanied by mural thickening (suggestive of continued disease activity), eventually culminating in aortic rupture.",
"   </p>",
"   <p>",
"    Vascular wall edema demonstrated by MRI, in the absence of other clinical evidence of active disease, does not appear to be a sufficient reason for more aggressive therapy. This point was illustrated by a study in which there was poor correlation between the appearance of MRI detected vessel wall edema and the presence or absence of active vasculitis as determined clinically, by subsequent development of stenotic or aneurysmal dilation or by pathologic examination of resected vessel walls [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tapering glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glucocorticoid dose can be gradually reduced when the symptoms and laboratory tests related to the inflammatory process have improved. We recommend a maximum reduction of 10 percent of the daily amount per week. Long-term low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy may be necessary to prevent progression of arterial stenoses. Glucocorticoids can be discontinued if the disease goes into remission, while the dose should be increased if exacerbations occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Preventing glucocorticoid adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the duration of glucocorticoid use and the cumulative dose cannot be predicted at the outset of treatment, attention to prevention of potential adverse effects of glucocorticoids is warranted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid-induced bone mineral loss &mdash; Prevention of glucocorticoid-induced osteoporosis is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Summarized briefly, supplementation with calcium and vitamin D are recommended. Prophylactic use of an oral bisphosphonate (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    ) can be initiated while awaiting results of an initial study of bone mineral density. If osteoporosis is present, full-dose regimens rather than prophylactic treatment are warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .) Or (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glucocorticoid-resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of all patients with Takayasu arteritis have chronic active disease for which glucocorticoid therapy alone does not provide sustained remissions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/5\">",
"     5",
"    </a>",
"    ]. The adjunctive use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and other agents may have some value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was evaluated in an open-label study of 18 such patients, 16 of whom were followed for a mean of almost three years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/5\">",
"     5",
"    </a>",
"    ]. Weekly administration of methotrexate (mean stable dose 17.1 mg) plus glucocorticoids resulted in remissions in 13 of 16 patients (81 percent). Relapse occurred in seven (44 percent) when the glucocorticoids were tapered near or to discontinuation. Retreatment again led to remission, and three of seven patients in this group successfully stopped glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Of those patients who achieved remission, eight (50 percent) sustained the remission at a mean of 18 months of follow-up; four patients in this group had not required either drug for a mean of 11 months. Disease progression occurred in three patients in spite of treatment. Further long-term studies are required to assess the durability of remission and the need for maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy in this subset of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    with glucocorticoids has been assessed in an uncontrolled series of 15 young women in India, all of whom had angiographic evidence of disease and in whom follow-up angiograms were performed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/6\">",
"     6",
"    </a>",
"    ]. All remitted within 12 weeks during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for six weeks followed by a taper to 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by 12 weeks) and azathioprine (2",
"    <span class=\"nowrap\">",
"     mg/kg/day).",
"    </span>",
"    Azathioprine was continued for one year at which time repeat angiography revealed no new arterial lesions and no worsening of the previously noted stenoses or aneurysms. There was, however, no improvement in the angiographic appearance. The combination was well-tolerated, and no adverse effects were reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Anti-TNF agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with anti-tumor necrosis factor (TNF)-alpha agents in difficult to treat patients with Takayasu arteritis (TA) is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. An uncontrolled series of 15 patients who required high doses of glucocorticoids to maintain remission and who relapsed while treated with other agents (or who refused retreatment with glucocorticoids) were treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (seven patients received an initial dose of 25 mg twice weekly) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (eight patients received 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    initially, at two weeks, at six weeks, and every four to eight weeks thereafter) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylaxis was used for those on high-dose glucocorticoids and a cytotoxic agent. Improvement was noted in 14 of 15 patients. Sustained remission was achieved in 10 patients who were able to discontinue glucocorticoids. Nine of the 14 patients required dose escalation to maintain disease control. A larger randomized controlled study of anti-TNF therapy for TA is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is very limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , which is commonly used in many other forms of systemic vasculitis. One case report suggested that it may not be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/9\">",
"     9",
"    </a>",
"    ]. Benefits have also been reported in at least eight patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , which has also shown benefit in a larger number of cases of patients with giant cell arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]; in three patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/15\">",
"     15",
"    </a>",
"    ]; and in one patient treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/16\">",
"     16",
"    </a>",
"    ]. Further study is required, but comparative randomized trials will be difficult given the small number of patients seen in individual centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the patient with disease refractory to glucocorticoids, we recommend trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    and reserve",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for those who have continued disease activity despite those medications. It is possible that anti-tumor necrosis factor agents will be useful in this setting as an alternative to cyclophosphamide, but additional evidence is needed to assess the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transluminal angioplasty or bypass grafts may be considered in late cases when irreversible arterial stenosis has occurred and when significant ischemic symptoms are present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Angioplasty is preferable when the lesions are amenable to catheter-based therapy. However, percutaneous intervention is less likely to be successful when stenoses or occlusions affect lengthy portions of an artery or when the artery is heavily scarred.",
"   </p>",
"   <p>",
"    Continued inflammation in a treated segment may result in restenosis following angioplasty, with or without stenting; restenosis is less likely following bypass grafting than angioplasty, when performed after initiation of treatment or when revascularization is followed by antiinflammatory therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aortic valve surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive aortic regurgitation (AR) may require surgical therapy either with valve replacement or with valve repair. Surgery is more difficult in this disorder since the tissue is fragile and inflamed. The general indications for surgery for AR and the available options are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term outcome after surgery for AR in Takayasu arteritis was evaluated in a series of 90 consecutive patients (mean age 49). Sixty-three underwent aortic valve replacement, and 27 underwent composite graft repair [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/22\">",
"     22",
"    </a>",
"    ]. The study was not designed to compare the two approaches, and the two groups had significant baseline differences. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In-hospital mortality was 5.5 percent, and 15-year survival was 76 percent.",
"     </li>",
"     <li>",
"      Detachment of the valve or graft occurred in 8.9 percent (in 11.1 percent with valve replacement and in 3.7 percent with valve repair, a difference that was not significant).",
"     </li>",
"     <li>",
"      Late dilation (&gt;50 mm) of the residual ascending aorta occurred in 8.9 percent (in 11.1 percent with valve replacement and in 3.7 percent with valve repair, a difference that was not significant).",
"     </li>",
"     <li>",
"      Active aortic inflammation was confirmed in intraoperative specimens from 10 patients; late valve or graft detachment occurred in four of these patients. Such patients had serologic evidence of inflammation (elevated serum C-reactive protein",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erythrocyte sedimentation rate &gt;20 mm). The authors treated patients with these findings with glucocorticoid therapy that was continued until normal values were attained.",
"     </li>",
"     <li>",
"      Outcomes appeared to be worse with aortic valve-sparing reimplantation, as three of four patients required subsequent aortic valve replacement for recurrent AR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H36#H36\">",
"       \"Course and management of chronic aortic regurgitation in adults\", section on 'Aortic valve-sparing reimplantation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Takayasu arteritis is a chronic disease. The degree of activity over time varies, with apparent exacerbations and reductions (or remissions) in the intensity of the inflammatory processes. The disease may eventually burn out.",
"   </p>",
"   <p>",
"    Vascular involvement tends to be progressive, although the short-term prognosis is favorable. In several follow-up studies, 80 to 90 percent of five-year survivals have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/17,23,24\">",
"     17,23,24",
"    </a>",
"    ]. One study investigating prognostic factors associated with this disease found two major predictors of outcome: the incidence of complications (Takayasu retinopathy, hypertension, aortic regurgitation, and aneurysm) and the presence of a progressive course [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/19\">",
"     19",
"    </a>",
"    ]. The 15-year survival was 66 and 96 percent for patients with and without a major complication, respectively, and was 68 and 93 percent for those with and without a progressive course, respectively. The presence of both a major complication and progressive course was the worst prognostic indicator (43 percent survival at 15 years). In contrast, no patient died who had neither of these manifestations. These variables may identify a subset of patients who require more aggressive medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical therapy.",
"   </p>",
"   <p>",
"    The long-term prognosis among patients who required surgical revascularization was addressed in a study of 106 such Japanese patients who followed for a mean of 19.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/25\">",
"     25",
"    </a>",
"    ]. Survival to hospital discharge was 89 percent; overall survival at 20 years was 73.5 percent. Anastomotic aneurysms developed in 13.8 percent of long-term survivors at various times following surgery. Lifelong surveillance for the development of this complication has been recommended by authors at one center [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3015/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27244917\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids, the mainstay of therapy for Takayasu arteritis (TA), effectively suppress the systemic symptoms and usually arrest disease progression. The normochromic anemia and elevated acute phase reactants also return to normal. Arterial stenosis may reverse, and ischemic symptoms may improve in early cases. However, the vascular response is diminished once fibrous tissue has formed in the involved vessels or once thrombosis has occurred. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use an initial single morning daily dose of 45 to 60 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in an average-sized adult patient. Computerized tomographic scanning or magnetic resonance imaging (MRI) can also be used to follow the response to treatment. However, vascular wall edema demonstrated by MRI, in the absence of other clinical evidence of active disease, does not appear to be a sufficient reason for more aggressive therapy. The glucocorticoid dose can be gradually reduced when the symptoms and laboratory tests related to the inflammatory process have improved. Long-term low-dose prednisone therapy may be necessary to prevent progression of arterial stenoses. Glucocorticoids can be discontinued if the disease goes into remission, while the dose should be increased if exacerbations occur. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial glucocorticoid dose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Assessing response to treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Tapering glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately one-half of all patients with Takayasu arteritis have chronic active disease for which glucocorticoid therapy alone does not provide sustained remissions. In patients with disease refractory to glucocorticoids, we recommend trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      and reserve",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for those who have continued disease activity despite those medications. Additional evidence is needed to assess the efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      in this setting. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Glucocorticoid-resistant disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Methotrexate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Azathioprine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Anti-TNF agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Other medications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous transluminal angioplasty or bypass grafts may be considered in late cases when irreversible arterial stenosis has occurred and when significant ischemic symptoms are present. Angioplasty is preferable when the lesions are amenable to catheter-based therapy. However, percutaneous intervention is less likely to be successful when stenoses or occlusions affect lengthy portions of an artery or when the artery is heavily scarred. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progressive aortic regurgitation (AR) may require surgical therapy either with valve replacement or with valve repair. Surgery is more difficult in this disorder since the tissue is fragile and inflamed. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Aortic valve surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"       \"Course and management of chronic aortic regurgitation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Takayasu arteritis is a chronic disease. The degree of activity over time varies, with apparent exacerbations and reductions (or remissions) in the intensity of the inflammatory processes. Vascular involvement tends to be progressive, although the short-term prognosis is favorable. The disease may eventually burn out. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/1\">",
"      Kerr GS. Takayasu's arteritis. Rheum Dis Clin North Am 1995; 21:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/2\">",
"      Hata A, Numano F. Magnetic resonance imaging of vascular changes in Takayasu arteritis. Int J Cardiol 1995; 52:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/3\">",
"      Sueyoshi E, Sakamoto I, Hayashi K. Aortic aneurysms in patients with Takayasu's arteritis: CT evaluation. AJR Am J Roentgenol 2000; 175:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/4\">",
"      Tso E, Flamm SD, White RD, et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/5\">",
"      Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/6\">",
"      Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 2003; 30:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/7\">",
"      Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/8\">",
"      Della Rossa A, Tavoni A, Merlini G, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) 2005; 44:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/9\">",
"      Mevorach D, Leibowitz G, Brezis M, Raz E. Induction of remission in a patient with Takayasu's arteritis by low dose pulses of methotrexate. Ann Rheum Dis 1992; 51:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/10\">",
"      Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/11\">",
"      Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012; 64:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/12\">",
"      Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141:w13156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/13\">",
"      Salvarani C, Magnani L, Catanoso MG, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-&alpha; blockers. Clin Exp Rheumatol 2012; 30:S90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/14\">",
"      Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012; 30:S98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/15\">",
"      Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999; 130:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/16\">",
"      Haberhauer G, Kittl EM, Dunky A, et al. Beneficial effects of leflunomide in glucocorticoid- and methotrexate-resistant Takayasu's arteritis. Clin Exp Rheumatol 2001; 19:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/17\">",
"      Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore) 1985; 64:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/18\">",
"      Rao SA, Mandalam KR, Rao VR, et al. Takayasu arteritis: initial and long-term follow-up in 16 patients after percutaneous transluminal angioplasty of the descending thoracic and abdominal aorta. Radiology 1993; 189:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/19\">",
"      Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994; 90:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/20\">",
"      Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol 2004; 31:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/21\">",
"      Park MC, Lee SW, Park YB, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology (Oxford) 2006; 45:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/22\">",
"      Matsuura K, Ogino H, Kobayashi J, et al. Surgical treatment of aortic regurgitation due to Takayasu arteritis: long-term morbidity and mortality. Circulation 2005; 112:3707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/23\">",
"      Ishikawa K. Natural history and classification of occlusive thromboaortopathy (Takayasu's disease). Circulation 1978; 57:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/24\">",
"      Eichhorn J, Sima D, Thiele B, et al. Anti-endothelial cell antibodies in Takayasu arteritis. Circulation 1996; 94:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3015/abstract/25\">",
"      Miyata T, Sato O, Koyama H, et al. Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation 2003; 108:1474.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8219 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3015=[""].join("\n");
var outline_f2_60_3015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27244917\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Initial glucocorticoid dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Assessing response to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tapering glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Preventing glucocorticoid adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glucocorticoid-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Anti-TNF agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aortic valve surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27244917\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8219|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/53/27474\" title=\"diagnostic image 1A\">",
"      Takayasu arteritis aneurysm 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/50/24355\" title=\"diagnostic image 1B\">",
"      Takayasu arteritis aneurysm 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8219|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/7/38011\" title=\"table 1\">",
"      Criteria for Takayasu arteritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_60_3016="Ultrasound oil cyst";
var content_f2_60_3016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Ultrasound oil cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 580px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Oil cyst (anti-radial). B) Oil cyst (radial). C) Mammographic appearance of oil cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3016=[""].join("\n");
var outline_f2_60_3016=null;
var title_f2_60_3017="Chylothorax PA";
var content_f2_60_3017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74111%7EPULM%2F64375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74111%7EPULM%2F64375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chylothorax post right pneumonectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple gas-liquid levels in the postpneumonectomy space, with cardiomediastinal shift to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chylothorax after esophagectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT shows large low attenuation right pleural effusion with inversion of the right hemidiaphragm and cardiomediastinal shift to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3017=[""].join("\n");
var outline_f2_60_3017=null;
var title_f2_60_3018="Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis";
var content_f2_60_3018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/60/3018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/60/3018/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/60/3018/contributors\">",
"     Anthony Bleyer, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/60/3018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/60/3018/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/60/3018/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/60/3018/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/60/3018/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/60/3018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis is carried out by a catheter made of a biocompatible material that is placed in a fistulous tract connecting the sterile peritoneum with the external, non-sterile environment. It is therefore not surprising that both the tract and the peritoneum are prone to bacterial infection either as a result of catheter colonization, from possible contamination at the time of the spike, or from an exit site or catheter tunnel infection.",
"   </p>",
"   <p>",
"    There are seven important issues to consider with exit site infections:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevention",
"     </li>",
"     <li>",
"      Evaluation of the exit site and diagnosis of infection",
"     </li>",
"     <li>",
"      Initial antibiotic therapy",
"     </li>",
"     <li>",
"      Resistant infection",
"     </li>",
"     <li>",
"      Indications for catheter removal",
"     </li>",
"     <li>",
"      Site and timing of new catheter placement",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Prevention/treatment",
"      </span>",
"      of recurrent infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic reviews these issues. Other topics including the microbiology and treatment of peritonitis and diagnosis of peritonitis in peritoneal dialysis patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12690226\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, the catheter becomes colonized with bacteria soon after catheter placement; these bacteria may secrete a biofilm which encourages further bacterial growth and protects the colonizing organisms from antimicrobial agents. This does not represent a clinical infection but can predispose to one. Similarly, the exit site tends to be colonized by bacteria. Again, this colonization does not represent a clinical infection but can result in eventual tissue invasion and subsequent infection, especially in the setting of exit site trauma.",
"   </p>",
"   <p>",
"    The bacteria colonizing the exit site are the same as those responsible for exit site infections, but somewhat different from those causing peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .) In a peritoneal dialysis population receiving no antimicrobial prophylaxis, approximately one-half of healthy exit sites are colonized by Staphylococcus aureus (S. aureus), which also accounts for over 50 percent of exit site infections. In these cases, other causes of bacterial exit site infection include Staphylococcus epidermidis (20 percent), Pseudomonas aeruginosa (8 percent), and Escherichia coli (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/1\">",
"     1",
"    </a>",
"    ]. Nasal carriage of S. aureus, common among patients undergoing peritoneal dialysis, also increases the risk of recurrent exit-site infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Prevention/treatment of recurrent infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With the widespread usage of prophylactic antimicrobial applications at the exit site, there has been a change in the organisms leading to exit site infections. One study identified several cases of exit site infection caused by atypical mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/3\">",
"     3",
"    </a>",
"    ] at one center, while another investigation noted the occurrence of several exit site infections caused by non-diphtheria corynebacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/4\">",
"     4",
"    </a>",
"    ]. In a study using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    cream at the exit site [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/5\">",
"     5",
"    </a>",
"    ], the causes of exit site infection were S. aureus in 33 percent, other gram positive organisms in 27 percent, yeast in 20 percent, sterile culture in 13 percent, and gram negative organisms in 7 percent. This increase in yeast exit site infections with gentamicin cream is a potential cause for concern and further study is warranted.",
"   </p>",
"   <p>",
"    Innovations in connectology and exit site bacterial prophylaxis have led to a reduced incidence of both peritonitis and exit site infections in patients on peritoneal dialysis. However, exit site infections are still a source of morbidity in these patients, and the rate of exit site infections parallels the rate of patient transfer from peritoneal dialysis to hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION OF CATHETER INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Exit site care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal chronic care of the exit site is desirable to help prevent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/6\">",
"     6",
"    </a>",
"    ]. The International Society for Peritoneal Dialysis published guidelines for practices relating to the exit-site of peritoneal catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a summary of the recommendations that have been made:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Acute care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After placement of the catheter, dressing changes are not needed until about 7 to 10 days post-operatively. If dressing changes are done, a peritoneal dialysis nurse should perform sterile dressing changes until the patient is trained and the exit site is well-healed. The site should be dry until it is well-healed, which precludes taking showers or baths, usually for a period of up to two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chronic care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exit sites should be washed daily or every other day with antibacterial soap or an antiseptic (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ). Cleansers may be individualized based upon allergies and should not be transferred to other containers because of the risk of contamination. Cleansers that are toxic to cells or the normal granulation tissue of the exit site, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , which is drying, should be avoided for routine care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The catheter should be immobile during cleaning, which helps prevent trauma to the site.",
"     </li>",
"     <li>",
"      Crusts should not be forcibly removed.",
"     </li>",
"     <li>",
"      The exit should be dabbed dry after cleaning. The use of a clean cloth or towel is sufficient for this purpose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antimicrobial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is recommended in addition to the normal daily exit site care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/9\">",
"     9",
"    </a>",
"    ]. This approach likely works, in part, by decreasing the number of potentially pathogenic bacteria that colonize the exit site; so if trauma occurs, there are few bacteria that can cause tissue invasion and an infection.",
"   </p>",
"   <p>",
"    Antimicrobial prophylaxis requires both a patient-oriented and center-oriented approach. Data regarding the prevalence of infections, organisms, and resistance patterns should be collected, and prophylactic therapy determined, based on the patterns of colonization and infection that are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Gentamicin cream",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    cream appears to be the optimal agent to prevent exit site infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. This was best shown in a prospective, randomized, double-blind study of 133 patients who were randomly assigned to the application of 0.1 percent gentamicin sulfate cream to the exit site or 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    cream [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/5\">",
"     5",
"    </a>",
"    ]. Each day, approximately 10 mg (a quarter-inch dab) was placed around the catheter with a cotton-tipped swab. At a median follow-up of eight months, benefits with gentamicin included significantly longer time to first catheter infection and a decrease in the peritonitis rate. Catheter infection rates were lower with gentamicin cream compared with mupirocin (0.23 versus 0.54 per year, respectively). There were no pseudomonas exit site infections in the gentamicin group versus six infections in the mupirocin group.",
"   </p>",
"   <p>",
"    However, other studies showed no difference in the exit site infection rate between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    cream [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As an example, in a prospective study that included 95 patients who were alternatively allocated to mupirocin versus gentamicin cream, the exit site infection rate was not different between the gentamicin and mupirocin groups (0.38 episodes versus 0.20 per patient-year, [p = 0.36]) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/10\">",
"     10",
"    </a>",
"    ]. The overall peritonitis rates were similar between the two groups. Patients in the mupirocin group had no gram positive exit site infections, while in patients in the gentamicin cream group approximately 50 percent of the infections were with gram positive bacteria, and 50 percent were with gram negative bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mupirocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     Mupirocin",
"    </a>",
"    is an antibiotic active against gram-positive organisms, and it has been used as an ointment to treat nasal carriage of S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Due to the discomfort of nasal application, topical application at the exit site has been the preferred form of usage.",
"   </p>",
"   <p>",
"    Intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    is preventative. The best data on the efficacy of intranasal mupirocin cream has come from the Mupirocin Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This randomized trial evaluated 267 patients on CAPD who were nasal carriers of S. aureus (as determined by culture of nasal swabs on two separate occasions). The patients were randomized to therapy with nasal mupirocin or placebo, given as a nasal ointment twice daily for five consecutive days every four weeks. The following benefits were noted in the mupirocin group after a maximum follow-up of 18 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower incidence of persistent nasal S. aureus carriage &mdash; 10 versus 48 percent with placebo",
"     </li>",
"     <li>",
"      A lower incidence of exit site infection due to S. aureus &mdash; 14 versus 44 episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to what was observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    cream, there were no differences in the rate of exit site infection due to other organisms or in the rate of tunnel infection or peritonitis, and there was no evidence of progressive resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Chronic application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ointment to the catheter exit site also prevents infection, possibly including peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/15-22\">",
"     15-22",
"    </a>",
"    ]. This was shown in a 2010 systematic review of 14 studies enrolling 1233 patients in which mupirocin was associated with a significantly lower risk of exit site infection (0.57, 95% CI 0.46-0.66) and peritonitis (0.41, 95% CI 0.24-0.54) due to all organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    prevents development of staph aureus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/23\">",
"     23",
"    </a>",
"    ]. While mupirocin diminishes the incidence of staph aureus peritonitis, it does not change that of gram negative infections. Therefore, the proportion of gram negative infections increases, but the rates of these infections do not change.",
"   </p>",
"   <p>",
"    Adverse consequences to the use of prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    cream may include floral changes at the exit site and the development of mupirocin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, one study that examined mupirocin resistance and methicillin resistance over a seven year period reported no increased prevalence in mupirocin resistance over this time period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, since mupirocin is not normally used in the treatment of infection, the emergence of mupirocin resistant S. aureus has limited clinical consequences. Mupirocin cream is the recommended form of therapy given that topical treatment with mupirocin ointment may result in damage to silicone rubber and polyurethane catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other prophylactic agents and approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic topical antimicrobial therapy has also been evaluated with agents other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    cream. As examples [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study was performed in 83 children comparing one center's experience with different prophylaxis regimens for exit site infections [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/28\">",
"       28",
"      </a>",
"      ]. The combination of sodium hypochlorite and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      results in a significant decline in gram negative peritonitis, infection-related catheter removal, and exit site infections compared with mupirocin alone. Although this option appears attractive, definitive conclusions cannot be drawn at this time.",
"     </li>",
"     <li>",
"      In a randomized trial of 164 patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      -otologic solution applied daily resulted in a marked decrease in exit site infections caused by S. aureus and pseudomonas aeruginosa [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An equivalent incidence of exit site infection was observed in a study that randomly assigned 100 patients to either sodium fucidate ointment or to weekly topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      applied to the exit site [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/30\">",
"       30",
"      </a>",
"      ]. However, there may not have been significant power to detect a clinical difference between the two treatments. There was some suggestion of relative benefit with mupirocin as there were no gram positive isolates in the mupirocin group, while 18.2 percent of the isolates in the sodium fucidate group were gram positive organisms.",
"     </li>",
"     <li>",
"      A multi-centered double blind randomized trial that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      and Polysporin Triple ointment (containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      , gramicidin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      ) among 201 patients showed no difference in the time to first PD-related infection (including exit site infections and peritonitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/33\">",
"       33",
"      </a>",
"      ]. However there was an increased rate of fungal exit site infections and fungal peritonitis among patients who received Polysporin Triple ointment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other methods to help prevent exit",
"    <span class=\"nowrap\">",
"     site/tunnel",
"    </span>",
"    infection have also been evaluated, including oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/20,34\">",
"     20,34",
"    </a>",
"    ]. In one randomized, controlled trial, for example, administration of oral rifampin (300 mg PO two times per day for the first five days of each 12-week interval) significantly decreased the incidence of exit site infections (0.26 versus 0.93 catheter infections per patient-year in the control group of no treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/34\">",
"     34",
"    </a>",
"    ]. However, a meta-analysis of four randomized studies in hemodialysis or peritoneal dialysis patients reported the development of S. aureus resistance to rifampin ranging from zero to 18.2 percent of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many different catheter-related interventions do not appear to provide added protection. This was best shown in a systematic review in which similar exit",
"    <span class=\"nowrap\">",
"     site/tunnel",
"    </span>",
"    infection rates were observed with various surgical approaches for PD catheter insertion (midline versus lateral insertions and standard insertion versus subcutaneous burying of the catheter until usage) or type of PD catheters (straight versus coiled) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medihoney, an antibacterial honey, has been shown to be beneficial in two trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. At present, it is available around the world and will soon be available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Miscellaneous considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other important aspects of infection prevention include chronic catheter immobilization, prevention of using an occlusive dressing so exit stays dry, and use of oral antibiotics for two to three days after an episode of exit site trauma. Although downward directed tunnels have been recommended in the ISPD catheter guidelines and the network 9 study showed a benefit for this type of exit site [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/39\">",
"     39",
"    </a>",
"    ], the data do not consistently demonstrate a benefit. We use swan neck catheters with a downward directed exit at our center.",
"   </p>",
"   <p>",
"    Pets are a frequent source of comfort to many, including dialysis patients. Sixty-three percent of households in the U.S. have at least one pet, and 41 percent of dogs sleep on their owner&rsquo;s beds [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/40\">",
"     40",
"    </a>",
"    ]. It is advised that pets remain out of the room when exchanges are performed. The effect of pets sleeping in bed with their owners should be considered if infections with zoonotic bacteria develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal chronic care of the exit site is desirable to help prevent infection, as delineated above. The use of 0.1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    sulfate cream applied daily would be the recommended agent of choice based on short term studies. However, monitoring for the development of antibiotic resistance should be performed.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     Mupirocin",
"    </a>",
"    does work as well and some would recommend alternating the two agents. We do not know the risk of developing antibiotic resistance with long term use of gentamicin cream and the implications of such resistance are much more significant than mupirocin resistance. Mupirocin resistance does not affect other antibiotics, nor is it a medication commonly used as the primary therapy for other infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE EXIT SITE AND DIAGNOSIS OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An exit site infection is considered to be present if there is purulent discharge from the exit site [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Redness or skin induration may or may not represent an infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8,42\">",
"     8,42",
"    </a>",
"    ]. Formation of a crust around the exit may not indicate infection. In addition, positive cultures from the exit site in the absence of inflammation do not indicate infection.",
"   </p>",
"   <p>",
"    Exit sites may progress from asymptomatic colonization to mild infection with increased crust formation and erythema surrounding the exit site, to serous and purulent drainage arising from the exit site, to abscess formation and tunnel infection. This spectrum of infection makes it difficult to precisely define the exact moment when an exit site infection develops. Nevertheless, early recognition is important so that therapy can be promptly instituted. In particular, any change from the patient's normal, healthy exit site should be viewed suspiciously as the advent of new infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Grading systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A system for grading exit sites through the spectrum of health and infection has been proposed (",
"    <a class=\"graphic graphic_table graphicRef61012 graphicRef73832 \" href=\"UTD.htm?36/48/37645\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A perfect exit site is greater than six months old and has mature epithelium present in the sinus tract. The sinus tract is usually dry, but may be damp or contain thick drainage. There is no erythema or serous drainage and crust forms no more frequently than every seven days.",
"     </li>",
"     <li>",
"      A good exit site has granulation tissue in the sinus tract with some epithelium and some mucosa present. The sinus may be moist or have thick drainage. A crust forms no more often than every two days.",
"     </li>",
"     <li>",
"      An equivocal exit site may have slightly exuberant granulation tissue around the sinus and has liquid drainage within the sinus. There is no pain, induration, or distinctly exuberant granulation tissue. The redness surrounding the catheter has a diameter of &le;13 mm.",
"     </li>",
"     <li>",
"      A chronically inflamed exit site has liquid external drainage, exuberant granulation tissue and a history of inflammation greater than four weeks. There is no pain, induration, or redness.",
"     </li>",
"     <li>",
"      An acutely inflamed exit site has pain, induration, redness with a diameter &ge;13 mm, exuberant granulation tissue, and a duration of infection less than four weeks.",
"     </li>",
"     <li>",
"      An external cuff infection without exit infection is associated with the expression of intermittent or chronic drainage (either spontaneously or after cuff pressure) and a normal appearing exit site.",
"     </li>",
"     <li>",
"      A traumatized exit varies in appearance, based upon both the severity of injury and when the site is examined after the trauma. It may be associated with pain, scabbing, and deterioration in grade of appearance of the exit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of the exit site begins with gross visual inspection, although a magnifying glass may be helpful for closer observation. The catheter tract should be milked to see if any drainage is present and observed for evidence of erythema overlying the tunnel, which is the part of the catheter between the two cuffs.",
"   </p>",
"   <p>",
"    Another grading system was developed by Pediatricians [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8\">",
"     8",
"    </a>",
"    ]. In this system, points are tallied, with an infection being assumed with an exit site score of 4 or greater. Purulent drainage alone was also considered sufficient to indicate infection (",
"    <a class=\"graphic graphic_table graphicRef73622 \" href=\"UTD.htm?31/9/31899\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians perform ultrasonography to assess whether tunnel infection is present and, if so, the initial severity of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/44\">",
"     44",
"    </a>",
"    ]. These findings may then be compared with that obtained after the completion of a therapeutic regimen (see below). Additional antibiotic therapy is unlikely to be beneficial in those without evidence of sonographic improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INITIAL ANTIBIOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of exit site infection should be directed at the stage of infection. If only increased crust formation and minimal erythema is present, for example, it is important to determine if there have been any inciting events and whether the patient is adhering to a strict regimen of hygiene and exit site care. The patient should be questioned about inadvertent trauma to the catheter in the past several days, since trauma is often associated with the development of infection. Any patient with trauma to their exit site should receive several days of prophylactic antibiotics. Culture is not helpful if no serous drainage is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mild infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild infection, with minimal erythema and no drainage, can be treated with topical antimicrobial agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    and dilute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . As an example, we recommend that the exit site be cleaned twice per day with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    followed by dilute hydrogen peroxide.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    eyedrops can also be used if one is suspicious of gram negative infection. An occlusive dressing should not be used, since this will trap any drainage and create moisture, which can facilitate bacterial growth.",
"   </p>",
"   <p>",
"    The exit site should be monitored daily by the patient. He or she should return to the physician in one week to evaluate the exit site and ascertain that the condition is improving. One could also use an oral antibiotic, although this may not be necessary in truly mild infections. However, both local and systemic care are prescribed at our center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Moderate infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach is different if drainage is present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/45\">",
"     45",
"    </a>",
"    ]. The drainage should be cultured, and the patient should be started on antibiotic(s). Gram stain of the drainage or the microbiologic history of a preceding exit site infection can help to direct therapy. In most cases, a staphylococcus species (primarily aureus or epidermidis) will be responsible for the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/1\">",
"     1",
"    </a>",
"    ]. Therefore, empiric therapy can be begun with a first-generation oral cephalosporin or a penicillinase-resistant penicillin (",
"    <a class=\"graphic graphic_table graphicRef67277 \" href=\"UTD.htm?33/42/34476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/43\">",
"     43",
"    </a>",
"    ]. Given the increased incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant organisms, vancomycin should not be used in routine therapy. As noted in the 2010 ISPD guidelines, oral antibiotic therapy is as effective as intraperitoneal antibiotic therapy, with the exception of the treatment of methicillin-resistant S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8,42\">",
"     8,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic regimen should be different if gram-negative infection is suspected. In this setting, the patient should be treated with an anti-pseudomonal antibiotic. We usually recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/43\">",
"     43",
"    </a>",
"    ]. Ciprofloxacin should not be taken at the same time as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    , calcium salts, iron, or magnesium supplements and milk, as these substances decrease the absorption and efficacy of ciprofloxacin. If the patient is under eighteen or cannot take ciprofloxacin, intraperitoneal treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    can be used. The 2010 ISPD guidelines suggest that this agent should preferably not be given as monotherapy since resistance develops rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric therapy may need to be based on local patterns of infection and resistance and also based on the type of exit site antimicrobial prophylaxis being used. In a study comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    cream for exit site infection prophylaxis, 9 of 15 infections in the gentamicin group were from gram positive organisms, and only one was from a gram negative organism (three were yeast infections and two were negative culture) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, in the mupirocin group, 17 of 29 exit site infections in the mupirocin group were from gram positive organisms, but there were also 9 of 29 infections from gram negative organisms.",
"   </p>",
"   <p>",
"    Treatment may be modified when the culture results are obtained. A summary of treatment recommendations from a year 2000 consensus panel of experts is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef62413 \" href=\"UTD.htm?36/57/37791\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/43\">",
"     43",
"    </a>",
"    ]; this is consistent with follow-up recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8,42\">",
"     8,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the organism is a staphylococcus species and there is no improvement after several days, then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    should be added to the regimen. Rifampin should not be given as single agent therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8,42\">",
"     8,42",
"    </a>",
"    ]. Rifampin has good tissue penetration and acts synergistically with anti-staphylococcal penicillins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . The patient should be warned not to wear contact lenses while on rifampin, since this drug enters tear secretions and may stain contact lenses orange.",
"   </p>",
"   <p>",
"    If the organism is a pseudomonas species, the probability of successful medical therapy decreases. In addition, even if the exit site infection appears to have resolved, pseudomonas peritonitis may occur in follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/46\">",
"     46",
"    </a>",
"    ]. If the response is slow or there is recurrent infection, a second antipseudomonal drug, such as intraperitoneal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , an aminoglycoside,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"     piperacillin",
"    </a>",
"    , imipenem-cilastin, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , may be added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8,42,43\">",
"     8,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic treatment is continued until the exit site appears healthy. Two weeks is the minimum period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8,42\">",
"     8,42",
"    </a>",
"    ], but treatment for three weeks is most likely necessary for Pseudomonas aeruginosa infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/42\">",
"     42",
"    </a>",
"    ]. However, although, there are anecdotal reports of curing an exit site infection with Pseudomonas, these infections often do not respond and require catheter removal. If appropriate antibiotic therapy fails to resolve the infection after prolonged therapy (eg, longer than three weeks), the catheter can be replaced or, if the cuffs are not involved, tunnel revision may be undertaken in combination with continued antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Indications for catheter removal'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Resistant infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    During prolonged antibiotic usage, prophylactic therapy against vaginal and peritoneal yeast infection with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    may be considered, particularly in centers with a high baseline rate of fungal peritonitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of a peritoneal dialysis cohort, an attempt was made to give oral prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      to all patients receiving antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/47\">",
"       47",
"      </a>",
"      ]. There were no cases of fungal peritonitis in individuals who received oral prophylaxis, which represented a significant decline in the rate of fungal peritonitis compared to historical controls.",
"     </li>",
"     <li>",
"      In a second study with historic controls, antifungal prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , given during antibiotic therapy, resulted in a significant decline in fungal peritonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/48\">",
"       48",
"      </a>",
"      ]. There were 12 episodes of secondary fungal peritonitis in 1832 patient-months without treatment in a historical cohort, and only two episodes in 1705 patient months in the fluconazole-treated cohort.",
"     </li>",
"     <li>",
"      In a prospective randomized trial, peritoneal dialysis patients who developed peritonitis or exit",
"      <span class=\"nowrap\">",
"       site/tunnel",
"      </span>",
"      infections were randomized to receive oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 mg every 48 hours) or placebo throughout the time of therapeutic antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/49\">",
"       49",
"      </a>",
"      ]. The rate of fungal peritonitis was lower among patients who received fluconazole compared to placebo (1.3 versus 6.6, respectively). Among patients who did not receive fluconazole, 10 cases of fungal peritonitis developed 30 to 60 days after peritonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal infections are a rare cause of exit site infection, and there is little literature regarding treatment of this disorder. It is important to ascertain that the fungus identified in the culture is not a contaminant. The catheter should usually be",
"    <strong>",
"     removed",
"    </strong>",
"    if there is definite fungal exit site infection to prevent progression to fungal peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RESISTANT INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the exit site remains infected after two weeks of antibiotics, it is important to make certain that the patient is complying with the therapeutic regimen. A thorough repeat examination should also be performed, including examination for evidence of tunnel infection, ie, infection occurring along the catheter between the two cuffs. This complication is manifested by erythema and tenderness in the area overlying the tunnel.",
"   </p>",
"   <p>",
"    One should also examine the exit site to see if the external cuff is exposed. If it is almost completely exposed, the cuff may move in and out of the exit like a piston, causing local trauma, disrupting healthy granulation tissue and causing an infection. If so, the exposed cuff should be shaved. If only partially exposed or if the cuff is involved, one may be able to surgically \"de-roof\" the tunnel, completely expose the cuff, and then remove it by shaving the cuff. This surgical procedure is performed under local anesthesia. The tissue surrounding the catheter and the cuff is debrided, and the cuff is removed (often called &ldquo;shaved&rdquo; &ndash; but we prefer the term removed) with an abrasive agent such as sandpaper or a Bovie scratch pad.",
"   </p>",
"   <p>",
"    Ultrasonography, CT scanning, or less often gallium scanning may be performed to see if an abscess is present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/50\">",
"     50",
"    </a>",
"    ]. Ultrasonography, for example, may show a fluid accumulation between the catheter or cuff and the surrounding soft tissue. If an ultrasound procedure were performed at presentation, the absence of sonographic improvement of a tunnel infection suggests that continued antibiotic therapy is unlikely to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the cuff is not exposed and there is no evidence of abscess or tunnel infection, then another two weeks of therapy may be helpful if the infection has not progressed. At this point, cuff de-roofing may be considered. In this procedure, also performed under local anesthesia, an incision is made to the depth of the outer cuff. Tissue surrounding the outer cuff and the outer cuff itself are removed.",
"   </p>",
"   <p>",
"    Several techniques have been developed in the attempt to rescue such infected catheters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conflicting results have been obtained with the cuff-shaving procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/1,51,52\">",
"       1,51,52",
"      </a>",
"      ]. In one study, cuff-shaving provided an effective salvage therapy for gram positive exit site infections considered unresponsive to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/52\">",
"       52",
"      </a>",
"      ]. Thirty-eight such patients underwent 41 cuff-shaving procedures. Seventeen of 34 infections due to S. aureus and two of two due to S. epidermidis were eliminated.",
"     </li>",
"     <li>",
"      Some success has been reported with another salvage technique, termed partial reimplantation. With this surgery, the infected area of the catheter is removed and the uninfected internal conduit is connected to a new divided catheter [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. In one study of 26 such operations (23 patients with refractory tunnel or exit site infections and 2 with near-cuff catheter perforations), all patients resumed PD after the surgery and, at follow-up, only one patient had suffered another episode of refractory exit-site infection six months after surgery. A modification of this technique is to connect the segments of the old and new catheter with a titanium extender which remains subcutaneous [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further clinical trials are necessary to determine the role for these techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CATHETER REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even the most resistant exit site infection will respond to catheter removal and replacement. Thus, the risks and inconvenience of this procedure must be balanced against the small but significant risk of fungal colonization and resulting peritonitis in the setting of prolonged antibiotic usage. Fungal peritonitis can be highly morbid, resulting in scarring of the peritoneal membrane, and the inability to perform further peritoneal dialysis in the future. Prolonged, unrealistic attempts to \"save the catheter\" must be avoided to prevent this outcome.",
"   </p>",
"   <p>",
"    Catheter removal is required for some exit site and tunnel infections. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is unlikely that tunnel infection can be cleared with antibiotics alone, particularly if there is no evidence of improvement sonographically. The catheter should definitely be removed if peritonitis is also present [",
"      <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8,42\">",
"       8,42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"       \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The catheter should be removed if the infection does not respond or progresses after several weeks of antibiotic therapy. (Cuff-shaving may be tried prior to catheter removal.) Pseudomonal infections are particularly difficult to clear with medical therapy.",
"     </li>",
"     <li>",
"      The catheter should be removed if a tunnel abscess is present. It should also be considered if peritonitis develops due to the same organism infecting the exit site, particularly if the infection is caused by S. aureus or pseudomonas. Development of peritonitis indicates that there is infection along the length of the catheter, which is extremely difficult to treat with antimicrobial agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all cases, perioperative antibiotics should be given [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/8\">",
"     8",
"    </a>",
"    ] and then continued for one to two weeks after catheter removal.",
"   </p>",
"   <p>",
"    In some centers, the catheter is removed by traction with the retention of the peritoneal or subcutaneous cuffs or both, rather than by surgical dissection. Occasionally, cuffs are left behind. However, this should be prevented because retained cuffs may be a source of local infections, possibly leading to sepsis. In one study, a change in removal practice from traction to surgical dissection resulted in a significant reduction in the incidence of local infections (0 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SITE AND TIMING OF NEW CATHETER PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is no peritonitis associated with the exit site infection, the infected catheter can be removed and a new catheter placed simultaneously in the opposite lower quadrant [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/57\">",
"     57",
"    </a>",
"    ]. This procedure is commonly performed in the pediatric population and has also been shown to be effective in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In one study, for example, simultaneous catheter placement and removal was successful in 30 of 36 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/58\">",
"     58",
"    </a>",
"    ]. In the remaining six, persistent infection developed in two and the procedure was not successful for technical reasons in four.",
"   </p>",
"   <p>",
"    A new catheter should",
"    <strong>",
"     not",
"    </strong>",
"    be placed at the time the infected catheter is removed if active peritonitis is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION/TREATMENT OF RECURRENT INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in evaluating the patient with recurrent exit site infection is to determine if the patient received a complete course of therapy for the first infection and if the organism responsible was sensitive to the antibiotic prescribed. Breaks in the proper maintenance and hygiene of the exit site should be identified, and the patient retrained as necessary.",
"   </p>",
"   <p>",
"    Tunnel infection should also be considered in the patient with recurrent exit site infection. We use ultrasonography or CT scanning for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Mupirocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    has not been used previously, it should be considered. This is discussed in the section on prevention (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Prevention of catheter infections'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Rifampin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged therapy with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    may be beneficial in the patient with recurrent infections due to S. aureus. In one randomized, controlled trial, for example, administration of oral rifampin (300 mg PO two times per day for the first five days of each 12-week interval) significantly decreased the incidence of exit site infections (0.26 versus 0.93 catheter infections per patient-year in the control group of no treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/60/3018/abstract/34\">",
"     34",
"    </a>",
"    ]. However this study has not been repeated and more contemporary data would be helpful in evaluating the utility of rifampin in this setting (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prevention of catheter infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12691197\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients on peritoneal dialysis, both the tract and the peritoneum are prone to bacterial infection either as a result of catheter colonization, from possible contamination at the time of the spike, or from an exit site or catheter tunnel infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevention of infection requires optimal chronic care of the exit site, including daily or every other day washing of the exit site and antimicrobial prophylaxis with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      cream. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention of catheter infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early recognition of exit site infection is important so that therapy can be promptly instituted. This generally requires close gross visual inspection of the exit site. The catheter tract should be milked to see if any drainage is present and observed for evidence of erythema overlying the tunnel. A system for grading exit sites through the spectrum of health and infection has been proposed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation of the exit site and diagnosis of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild infection can be treated with topical antimicrobial agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      and dilute",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      . Moderate infection with drainage requires culture of drainage and an oral antibiotic. Gram stain of the drainage or the microbiologic history of a preceding exit site infection can help to direct therapy. If a gram-negative infection is suspected, the patient should be treated with an anti-pseudomonal antibiotic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      . Empiric therapy may need to be based on local patterns of infection and resistance and also based on the type of exit site antimicrobial prophylaxis being used. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Initial antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the exit site remains infected after two weeks of antibiotics, compliance should be ensured and a thorough repeat examination performed. One should also examine the exit site to see if the external cuff is exposed since an exposed cuff may cause infection. Ultrasonography, CT scanning, or less often gallium scanning may be performed to exclude an abscess. If the cuff is not exposed and there is no evidence of abscess or tunnel infection, additional antibiotic therapy may be attempted or salvage techniques may be employed to rescue the infected catheters. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Resistant infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter removal is required for some exit site and tunnel infections such as those complicated by a tunnel abscess or peritonitis, or if the infection does not respond or progresses after several weeks of antibiotic therapy. In all cases, perioperative antibiotics should be given and then continued for one to two weeks after catheter removal. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Indications for catheter removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is no peritonitis associated with the exit site infection, the infected catheter can be removed and a new catheter placed simultaneously in the opposite lower quadrant. A new catheter should",
"      <strong>",
"       not",
"      </strong>",
"      be placed at the time the infected catheter is removed if active peritonitis is present. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Site and timing of new catheter placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first step in the evaluation of recurrent exit site infection is to determine if the patient received a complete course of therapy for the first infection and if the organism responsible was sensitive to the antibiotic prescribed. Breaks in the proper maintenance and hygiene of the exit site should be identified, and the patient retrained as necessary. Tunnel infection should be excluded by ultrasonography or CT scanning.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       Mupirocin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      should be considered. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prevention/treatment of recurrent infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/1\">",
"      Scalamogna A, Castelnovo C, De Vecchi A, Ponticelli C. Exit-site and tunnel infections in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1991; 18:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/2\">",
"      Nouwen JL, Fieren MW, Snijders S, et al. Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. Kidney Int 2005; 67:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/3\">",
"      Tse KC, Lui SL, Cheng VC, et al. A cluster of rapidly growing mycobacterial peritoneal dialysis catheter exit-site infections. Am J Kidney Dis 2007; 50:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/4\">",
"      Schiffl, H, Mucke, C, and Lang, SM. Exit-site infections by non-diphtheria corynebacteria in CAPD. Perit Dial In 2003; 24:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/5\">",
"      Bernardini J, Bender F, Florio T, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/6\">",
"      O'Seaghdha CM, Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int 2005; 25:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/7\">",
"      Gokal R, Alexander S, Ash S, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. (Official report from the International Society for Peritoneal Dialysis). Perit Dial Int 1998; 18:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/8\">",
"      Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/9\">",
"      Piraino B, Bernardini J, Bender FH. An analysis of methods to prevent peritoneal dialysis catheter infections. Perit Dial Int 2008; 28:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/10\">",
"      Chu KH, Choy WY, Cheung CC, et al. A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. Perit Dial Int 2008; 28:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/11\">",
"      Mahaldar A, Weisz M, Kathuria P. Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis. Adv Perit Dial 2009; 25:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/12\">",
"      P&eacute;rez-Font&aacute;n M, Rosales M, Rodr&iacute;guez-Carmona A, et al. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial 1992; 8:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/13\">",
"      Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group. J Am Soc Nephrol 1996; 7:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/14\">",
"      Strippoli GF, Tong A, Johnson D, et al. Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. Am J Kidney Dis 2004; 44:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/15\">",
"      Thodis E, Bhaskaran S, Pasadakis P, et al. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/16\">",
"      Casey M, Taylor J, Clinard P, et al. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients. Perit Dial Int 2000; 20:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/17\">",
"      Ritzau J, Hoffman RM, Tzamaloukas AH. Effect of preventing Staphylococcus aureus carriage on rates of peritoneal catheter-related staphylococcal infections. Literature synthesis. Perit Dial Int 2001; 21:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/18\">",
"      Piraino B, Bernardini J, Florio T, Fried L. Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. Perit Dial Int 2003; 23:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/19\">",
"      Conly JM, Vas S. Increasing mupirocin resistance of Staphylococcus aureus in CAPD--should it continue to be used as prophylaxis? Perit Dial Int 2002; 22:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/20\">",
"      Bernardini J, Piraino B, Holley J, et al. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/21\">",
"      Xu G, Tu W, Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2010; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/22\">",
"      Lim CT, Wong KS, Foo MW. The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital. Nephrol Dial Transplant 2005; 20:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/23\">",
"      Piraino B. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Was it effective? Nephrol Dial Transplant 2010; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/24\">",
"      P&eacute;rez-Font&aacute;n M, Rosales M, Rodr&iacute;guez-Carmona A, et al. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/25\">",
"      Lobbedez T, Gardam M, Dedier H, et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years. Nephrol Dial Transplant 2004; 19:3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/26\">",
"      Cavdar C, Atay T, Zeybel M, et al. Emergence of resistance in staphylococci after long-term mupirocin application in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2004; 20:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/27\">",
"      Khandelwal M, Bailey S, Izatt S, et al. Structural changes in silicon rubber peritoneal dialysis catheters in patients using mupirocin at the exit site. Int J Artif Organs 2003; 26:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/28\">",
"      Chua AN, Goldstein SL, Bell D, Brewer ED. Topical mupirocin/sodium hypochlorite reduces peritonitis and exit-site infection rates in children. Clin J Am Soc Nephrol 2009; 4:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/29\">",
"      Montenegro J, Saracho R, Aguirre R, et al. Exit-site care with ciprofloxacin otologic solution prevents polyurethane catheter infection in peritoneal dialysis patients. Perit Dial Int 2000; 20:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/30\">",
"      Danguilan RA, Evangelista LP, Abrenica MS, Rondilla SM. Comparative study of mupirocin and sodium fucidate in the prophylaxis of exit-site infections in CAPD patients. Perit Dial Int 2003; 23:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/31\">",
"      Pommer W, Brauner M, Westphale HJ, et al. Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients: silver ring prophylaxis at the catheter exit study. Am J Kidney Dis 1998; 32:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/32\">",
"      Crabtree JH, Burchette RJ, Siddiqi RA, et al. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int 2003; 23:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/33\">",
"      McQuillan RF, Chiu E, Nessim S, et al. A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study. Clin J Am Soc Nephrol 2012; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/34\">",
"      Zimmerman SW, Ahrens E, Johnson CA, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991; 18:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/35\">",
"      Falagas ME, Fragoulis KN, Bliziotis IA. Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure--a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/36\">",
"      Strippoli GF, Tong A, Johnson D, et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials. J Am Soc Nephrol 2004; 15:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/37\">",
"      Johnson DW, Clark C, Isbel NM, et al. The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. Perit Dial Int 2009; 29:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/38\">",
"      Johnson DW, van Eps C, Mudge DW, et al. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J Am Soc Nephrol 2005; 16:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/39\">",
"      Golper TA, Brier ME, Bunke M, et al. Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Am J Kidney Dis 1996; 28:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/40\">",
"      Broughton A, Verger C, Goffin E. Pets-related peritonitis in peritoneal dialysis: companion animals or trojan horses? Semin Dial 2010; 23:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/41\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/42\">",
"      Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/43\">",
"      Keane WF, Bailie GR, Boeschoten E, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000; 20:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/44\">",
"      Kwan TH, Tong MK, Siu YP, et al. Ultrasonography in the management of exit site infections in peritoneal dialysis patients. Nephrology (Carlton) 2004; 9:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/45\">",
"      Twardowski ZJ, Prowant BF. Current approach to exit-site infections in patients on peritoneal dialysis. Nephrol Dial Transplant 1997; 12:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/46\">",
"      Kazmi HR, Raffone FD, Kliger AS, Finkelstein FO. Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1992; 2:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/47\">",
"      Z&aacute;ruba K, Peters J, Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience. Am J Kidney Dis 1991; 17:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/48\">",
"      Wadhwa NK, Suh H, Cabralda T. Antifungal prophylaxis for secondary fungal peritonitis in peritoneal dialysis patients. Adv Perit Dial 1996; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/49\">",
"      Restrepo C, Chacon J, Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. Perit Dial Int 2010; 30:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/50\">",
"      Vychytil A, Lilaj T, Lorenz M, et al. Ultrasonography of the catheter tunnel in peritoneal dialysis patients: what are the indications? Am J Kidney Dis 1999; 33:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/51\">",
"      Piraino, B, Bernardini, J, Peitzman, A, Sorkin, M. Failure of peritoneal catheter cuff shaving to eradicate infection. Perit Dial Bull 1987; 7:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/52\">",
"      Scalamogna A, De Vecchi A, Maccario M, et al. Cuff-shaving procedure. A rescue treatment for exit-site infection unresponsive to medical therapy. Nephrol Dial Transplant 1995; 10:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/53\">",
"      Wu YM, Tsai MK, Chao SH, et al. Surgical management of refractory exit-site/tunnel infection of Tenckhoff catheter: technical innovations of partial replantation. Perit Dial Int 1999; 19:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/54\">",
"      Clou&acirc;tre Y, Cartier P, Charbonneau R, et al. Outpatient CAPD catheter salvage for persistent exit-site/tunnel infection. Nephrol Dial Transplant 2000; 15:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/55\">",
"      Fukasawa M, Matsushita K, Tanabe N, et al. A novel salvage technique that does not require catheter removal for exit-site infection. Perit Dial Int 2002; 22:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/56\">",
"      Elkabir JJ, Riaz AA, Agarwal SK, Williams G. Delayed complications following Tenckhoff catheter removal. Nephrol Dial Transplant 1999; 14:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/57\">",
"      Singhal MK, Vas SI, Oreopoulos DG. Treatment of peritoneal dialysis catheter-related infections by simultaneous catheter removal and replacement. Is it safe? Perit Dial Int 1998; 18:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/58\">",
"      Swartz R, Messana J, Reynolds J, Ranjit U. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections. Kidney Int 1991; 40:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/59\">",
"      Lui SL, Yip T, Tse KC, et al. Treatment of refractory pseudomonas aeruginosa exit-site infection by simultaneous removal and reinsertion of peritoneal dialysis catheter. Perit Dial Int 2005; 25:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/60/3018/abstract/60\">",
"      Plum J, Sudkamp S, Grabensee B. Results of ultrasound-assisted diagnosis of tunnel infections in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1994; 23:99.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1888 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3018=[""].join("\n");
var outline_f2_60_3018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12691197\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12690226\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION OF CATHETER INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Exit site care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Acute care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chronic care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antimicrobial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Gentamicin cream",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mupirocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other prophylactic agents and approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Miscellaneous considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION OF THE EXIT SITE AND DIAGNOSIS OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Grading systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INITIAL ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mild infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Moderate infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RESISTANT INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INDICATIONS FOR CATHETER REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SITE AND TIMING OF NEW CATHETER PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION/TREATMENT OF RECURRENT INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Mupirocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Rifampin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12691197\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1888\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1888|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/57/37791\" title=\"algorithm 1\">",
"      Dx and rx exit site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1888|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/46/1773\" title=\"table 1A\">",
"      PD cath exit site appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/28/7628\" title=\"table 1B\">",
"      PD cath sinus appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/9/31899\" title=\"table 2\">",
"      Exit site scoring system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/42/34476\" title=\"table 3\">",
"      Oral antibiotics used in exit-site and tunnel infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=related_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=related_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_60_3019="Psychosoc issues thal past";
var content_f2_60_3019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Psychosocial burden of thalassemia in the past",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Stigmatization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Secrecy about the illness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Isolation of patient and family",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physical handicap",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Absence of sexual development",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fear of dying before adulthood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fear of social rejection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dependency",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Politis, C. The psychosocial impact of chronic illness. Cooley's anemia, Seventh Symposium. Ann N Y Acad Sci 1998; 850:349.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3019=[""].join("\n");
var outline_f2_60_3019=null;
var title_f2_60_3020="Rx MRSA skin infections in children";
var content_f2_60_3020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing for selected oral antimicrobials for suspected methicillin-resistant Staphylococcus aureus skin and soft-tissue infections in children older than 30 days",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (TMP-SMX)*",
"       </td>",
"       <td>",
"        8 to 12 mg/kg per day of TMP, 40 to 60 mg/kg per day of SMX in 2 doses; maximum daily dose 320 mg of TMP, 1.6 g SMX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        30 to 40 mg/kg per day in 3 to 4 doses; maximum daily dose 600 mg to 1.8 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline*",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        2 to 4 mg/kg per day in 1 to 2 doses; maximum daily dose 100 to 200 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linezolid",
"       </td>",
"       <td>",
"        <p>",
"         &lt;12 years: 30 mg/kg per day in 3 doses",
"        </p>",
"        <p>",
"         &ge;12 years: 600 mg twice per day",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Does not have activity against",
"     <em>",
"      Streptococcus pyogenes",
"     </em>",
"     (group A streptococcus).",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      If the prevalence of clindamycin resistance in the community is low. D testing required to evaluate for inducible resistance (see text).",
"      <br>",
"       &Delta; Should not be used in children &lt;8 years of age.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        American Academy of Pediatrics. Antibacterial drugs for pediatric patients beyond the newborn period. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.810.",
"       </li>",
"       <li>",
"        Liu C, Bayer A, Cosgrove SE, et, al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3020=[""].join("\n");
var outline_f2_60_3020=null;
var title_f2_60_3021="Food-borne diseases I";
var content_f2_60_3021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <em>",
"         Bacillus",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Vomiting toxin",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        1-6 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Vomiting, some patients with diarrhea; fever uncommon",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism from stool of two or more ill persons and not from stool of controls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Isolation of &ge;10",
"        <sup>",
"         5",
"        </sup>",
"        organisms/g from epidemiologically implicated food, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Diarrheal toxin",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        6-24 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Diarrhea, abdominal cramps, and vomiting in some patients; fever uncommon",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism from stool of two or more ill persons and not from stool of controls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Isolation of &ge;10",
"        <sup>",
"         5",
"        </sup>",
"        organisms/g from epidemiologically implicated food, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <em>",
"         Brucella",
"        </em>",
"       </td>",
"       <td>",
"        Several days to several months usually &gt;30 days",
"       </td>",
"       <td>",
"        Weakness, fever, headache, sweats, chills, arthralgia, weight loss, splenomegaly",
"       </td>",
"       <td>",
"        Two or more ill persons and isolation of organism in culture of blood or bone marrow, greater than fourfold increase in standard agglutination titer (SAT) over several wks, or single SAT titer &ge;1:160 in person who has compatible clinical symptoms and history of exposure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Campylobacter",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        2-10 days, usually 2-5 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea (often bloody), abdominal pain, fever",
"       </td>",
"       <td>",
"        Isolation of organism from clinical specimens from two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Clostridium botulinum",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        2 hrs-8 days, usually 12-48 hours",
"       </td>",
"       <td rowspan=\"3\">",
"        Illness of variable severity; common symptoms are diplopia, blurred vision, and bulbar weakness; paralysis, which is usually descending and bilateral, may progress rapidly",
"       </td>",
"       <td>",
"        Detection of botulinal toxin in serum, stool, gastric contents, or implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of organism from stool or intestine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3021=[""].join("\n");
var outline_f2_60_3021=null;
var title_f2_60_3022="Predict organ confined prost CA";
var content_f2_60_3022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Partin tables to predict organ-confined prostate cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gleason score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical Stage T1c",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical Stage T2a",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical Stage T2b",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical Stage T2c",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Prediction",
"of probability of organ-confined disease:*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Serum",
"PSA = 0.0-2.5 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2-4",
"       </td>",
"       <td>",
"        95 (89-99)",
"       </td>",
"       <td>",
"        91 (79-98)",
"       </td>",
"       <td>",
"        88 (73-97)",
"       </td>",
"       <td>",
"        86 (71-97)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5-6",
"       </td>",
"       <td>",
"        90 (88-93)",
"       </td>",
"       <td>",
"        81 (77-85)",
"       </td>",
"       <td>",
"        75 (69-81)",
"       </td>",
"       <td>",
"        73 (63-81)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3 + 4 = 7",
"       </td>",
"       <td>",
"        79 (74-85)",
"       </td>",
"       <td>",
"        64 (56-71)",
"       </td>",
"       <td>",
"        54 (46-63",
"       </td>",
"       <td>",
"        51 (38-63)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4 + 3 = 7",
"       </td>",
"       <td>",
"        71 (62-79)",
"       </td>",
"       <td>",
"        53 (43-63)",
"       </td>",
"       <td>",
"        43 (33-54)",
"       </td>",
"       <td>",
"        39 (26-54)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        8-10",
"       </td>",
"       <td>",
"        66 (54-76)",
"       </td>",
"       <td>",
"        47 (35-59)",
"       </td>",
"       <td>",
"        37 (26-49)",
"       </td>",
"       <td>",
"        34 (21-48)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Serum",
"PSA = 2.6-4.0 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2-4",
"       </td>",
"       <td>",
"        92 (82-98)",
"       </td>",
"       <td>",
"        85 (69-96)",
"       </td>",
"       <td>",
"        80 (61-95)",
"       </td>",
"       <td>",
"        78 (58-94)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5-6",
"       </td>",
"       <td>",
"        84 (81-86)",
"       </td>",
"       <td>",
"        71 (66-75)",
"       </td>",
"       <td>",
"        63 (57-69)",
"       </td>",
"       <td>",
"        61 (50-70)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3 + 4 = 7",
"       </td>",
"       <td>",
"        68 (62-74)",
"       </td>",
"       <td>",
"        50 (43-57)",
"       </td>",
"       <td>",
"        41 (33-48)",
"       </td>",
"       <td>",
"        38 (27-50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4 + 3 = 7",
"       </td>",
"       <td>",
"        58 (48-67)",
"       </td>",
"       <td>",
"        39 (30-48)",
"       </td>",
"       <td>",
"        30 (22-39)",
"       </td>",
"       <td>",
"        27 (18-40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        8-10",
"       </td>",
"       <td>",
"        52 (41-63)",
"       </td>",
"       <td>",
"        33 (24-44)",
"       </td>",
"       <td>",
"        25 (17-34)",
"       </td>",
"       <td>",
"        23 (14-34)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Serum",
"PSA = 4.1-6.0 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2-4",
"       </td>",
"       <td>",
"        90 (78-98)",
"       </td>",
"       <td>",
"        81 (63-95)",
"       </td>",
"       <td>",
"        75 (55-93)",
"       </td>",
"       <td>",
"        73 (52-93)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5-6",
"       </td>",
"       <td>",
"        80 (78-83)",
"       </td>",
"       <td>",
"        66 (62-70)",
"       </td>",
"       <td>",
"        57 (52-63)",
"       </td>",
"       <td>",
"        55 (44-64)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3 + 4 = 7",
"       </td>",
"       <td>",
"        63 (58-68)",
"       </td>",
"       <td>",
"        44 (39-50)",
"       </td>",
"       <td>",
"        35 (29-40)",
"       </td>",
"       <td>",
"        31 (23-41)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4 + 3 = 7",
"       </td>",
"       <td>",
"        52 (43-60)",
"       </td>",
"       <td>",
"        33 (25-41)",
"       </td>",
"       <td>",
"        25 (18-32)",
"       </td>",
"       <td>",
"        21 (14-31)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        8-10",
"       </td>",
"       <td>",
"        46 (36-56)",
"       </td>",
"       <td>",
"        28 (20-37)",
"       </td>",
"       <td>",
"        21 (14-29)",
"       </td>",
"       <td>",
"        18 (11-28)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Serum",
"PSA 6.1-10 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2-4",
"       </td>",
"       <td>",
"        87 (73-97)",
"       </td>",
"       <td>",
"        76 (56-94)",
"       </td>",
"       <td>",
"        69 (47-91)",
"       </td>",
"       <td>",
"        67 (45-91)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5-6",
"       </td>",
"       <td>",
"        75 (72-77)",
"       </td>",
"       <td>",
"        58 (54-61)",
"       </td>",
"       <td>",
"        49 (43-54)",
"       </td>",
"       <td>",
"        46 (36-56)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3 + 4 = 7",
"       </td>",
"       <td>",
"        54 (49-59)",
"       </td>",
"       <td>",
"        35 (30-40)",
"       </td>",
"       <td>",
"        26 (22-31)",
"       </td>",
"       <td>",
"        24 (17-32)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4 + 3 = 7",
"       </td>",
"       <td>",
"        43 (35-51)",
"       </td>",
"       <td>",
"        25 (19-32)",
"       </td>",
"       <td>",
"        19 (14-25)",
"       </td>",
"       <td>",
"        16 (10-24)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        8-10",
"       </td>",
"       <td>",
"        37 (28-46)",
"       </td>",
"       <td>",
"        21 (15-28)",
"       </td>",
"       <td>",
"        15 (10-21)",
"       </td>",
"       <td>",
"        13 (8-20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Serum",
"PSA &gt;10 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2-4",
"       </td>",
"       <td>",
"        80 (61-95)",
"       </td>",
"       <td>",
"        65 (43-89)",
"       </td>",
"       <td>",
"        57 (35-86)",
"       </td>",
"       <td>",
"        54 (32-85)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5-6",
"       </td>",
"       <td>",
"        62 (58-64)",
"       </td>",
"       <td>",
"        42 (38-46)",
"       </td>",
"       <td>",
"        33 (28-38)",
"       </td>",
"       <td>",
"        30 (21-38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3 + 4 = 7",
"       </td>",
"       <td>",
"        37 (32-42)",
"       </td>",
"       <td>",
"        20 (17-24)",
"       </td>",
"       <td>",
"        14 (11-17)",
"       </td>",
"       <td>",
"        11 (7-17)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4 + 3 = 7",
"       </td>",
"       <td>",
"        27 (21-34)",
"       </td>",
"       <td>",
"        14 (10-18)",
"       </td>",
"       <td>",
"        9 (6-13)",
"       </td>",
"       <td>",
"        7 (4-12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        8-10",
"       </td>",
"       <td>",
"        22 (16-30)",
"       </td>",
"       <td>",
"        11 (7-15)",
"       </td>",
"       <td>",
"        7 (4-10)",
"       </td>",
"       <td>",
"        &nbsp; 6 (3-10)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PSA: prostate specific antigen.",
"     <br>",
"      * All numbers represent percent predictive probabilities (95 percent confidence interval).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Partin, AW, et al. Urology 2001; 58:845.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3022=[""].join("\n");
var outline_f2_60_3022=null;
var title_f2_60_3023="Lab identification of strep";
var content_f2_60_3023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Microbiologic characteristics of beta-hemolytic streptococci (A,C,G) of human and animal origin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 425px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PYR: pyrrolidonyl arylamidase; VP: Voges Proskauer reactions; BGUR: Beta glucuronidase.",
"     <br>",
"      * Called S. milleri or S. anginosus group.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_60_3023=[""].join("\n");
var outline_f2_60_3023=null;
